



HU000030844T2



(19) **HU**

(11) Lajstromszám: **E 030 844**

(13) **T2**

MAGYARORSZÁG
Szellemi Tulajdon Nemzeti Hivatala

EURÓPAI SZABADALOM **SZÖVEGÉNEK FORDÍTÁSA**

(21) Magyar ügyszám: **E 05 788492**

(22) A bejelentés napja: **2005. 09. 27.**

(96) Az európai bejelentés bejelentési száma:
EP 20050788492

(97) Az európai bejelentés közzétételi adatai:
EP 1799269 A2 **2006. 04. 06.**

(97) Az európai szabadalom megadásának meghirdetési adatai:
EP 1799269 B1 **2016. 09. 07.**

(51) Int. Cl.: **C12N 151/13**

A61K 317/13

(2006.01)

A61P 13/12

(2006.01)

A61P 17/14

(2006.01)

A61P 25/00

(2006.01)

A61P 27/16

(2006.01)

C07H 21/02

(2006.01)

(86) A nemzetközi (PCT) bejelentési szám:

PCT/IL 05/001035

(87) A nemzetközi közzétételi szám:

WO 06035434

(30) Elsőbbségi adatai:

613991 P	2004. 09. 28.	US
658196 P	2005. 03. 02.	US
703020 P	2005. 07. 26.	US

(73) Jogosult(ak):

**Quark Pharmaceuticals, Inc., Fremont,
California 94555 (US)**

(72) Feltaláló(k):

FEINSTEIN, Elena, Rehovot (IL)
ZURR, Daniel, Herzlia Pituach (IL)
EHRLICH, Shai, Walnut Creek, California CA 94598 (US)

(74) Képviselő:

**Arinova Szabadalmi és Védjegy Iroda,
Budapest**

(54) **Oligoribonukleotidok és azok alkalmazási eljárásai alopécia, akut veseelégtelenség és más betegségek kezelésére**

Az európai szabadalom ellen, megadásának az Európai Szabadalmi Közlönyben való meghirdetésétől számított kilenc hónapon belül, felszólalást lehet benyújtani az Európai Szabadalmi Hivatalnál. (Európai Szabadalmi Egyezmény 99. cikk(1))

A fordítást a szabadalmas az 1995. évi XXXIII. törvény 84/H. §-a szerint nyújtotta be. A fordítás tartalmi helyességét a Szellemi Tulajdon Nemzeti Hivatala nem vizsgálta.



(19)



(11)

EP 1 799 269 B1

(12)

EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention of the grant of the patent:

07.09.2016 Bulletin 2016/36

(51) Int Cl.:

C12N 15/113 (2010.01) **A61K 31/713** (2006.01)**C07H 21/02** (2006.01) **A61P 13/12** (2006.01)**A61P 17/14** (2006.01)**A61P 25/00** (2006.01)**A61P 27/16** (2006.01)

(21) Application number: 05788492.6

(22) Date of filing: 27.09.2005

(86) International application number:
PCT/IL2005/001035

(87) International publication number:
WO 2006/035434 (06.04.2006 Gazette 2006/14)

(54) OLIGORIBONUCLEOTIDES AND METHODS OF USE THEREOF FOR TREATMENT OF ALOPECIA, ACUTE RENAL FAILURE AND OTHER DISEASES

OLIGORIBONUKLEOTIDE UND ANWENDUNGSVERFAHREN DAFÜR ZUR BEHANDLUNG VON ALOPEZIE, AKUTER NIERENINSUFFIZIENZ UND ANDEREN ERKRANKUNGEN

OLIGORIBONUCLÉOTIDES ET PROCÉDÉS D'UTILISATION ASSOCIÉS POUR LE TRAITEMENT DE L'ALOPÉCIE, DES INSUFFISANCES RÉNALES AIGUËS ET D'AUTRES MALADIES

(84) Designated Contracting States:

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI
SK TR

(30) Priority: 28.09.2004 US 613991 P
02.03.2005 US 658196 P
26.07.2005 US 703020 P

(43) Date of publication of application:
27.06.2007 Bulletin 2007/26

(73) Proprietor: Quark Pharmaceuticals, Inc.
Fremont, California 94555 (US)

(72) Inventors:

- FEINSTEIN, Elena
Rehovot (IL)
- ZURR, Daniel
Herzlia Pituach (IL)
- EHRLICH, Shai
Walnut Creek, California CA 94598 (US)

(74) Representative: Almond-Martin, Carol et al
Ernest Gutmann - Yves Plasseraud S.A.S.
3, rue Auber
75009 Paris (FR)

(56) References cited:

WO-A2-00/44364 WO-A2-03/064625
WO-A2-2004/015107 US-A1- 2004 014 956
US-A1- 2007 031 844

- BOTCHKAREV V A ET AL: "p53 is essential for chemotherapy-induced hair loss", CANCER RESEARCH, vol. 60, no. 18, 15 September 2000 (2000-09-15), pages 5002-5006, XP002291252, ISSN: 0008-5472
- M ZHANG: "Pifithrin-[alpha] suppresses p53 and protects cochlear and vestibular hair cells from cisplatin-induced apoptosis", NEUROSCIENCE, vol. 120, no. 1, 4 August 2003 (2003-08-04), pages 191-205, XP55014479, ISSN: 0306-4522
- KELLY K J ET AL: "P53 mediates the apoptotic response to GTP depletion after renal ischemia-reperfusion: Protective role of a p53 inhibitor", JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, vol. 14, no. 1, 2003, pages 128-138, XP002632231, ISSN: 1046-6673
- SUPAVEKIN SUROJ ET AL: "Differential gene expression following early renal ischemia/reperfusion.", KIDNEY INTERNATIONAL, vol. 63, no. 5, May 2003 (2003-05), pages 1714-1724, XP55014248, ISSN: 0085-2538

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

Description

[0001] Throughout this application various patent and scientific publications are cited. The disclosures for these publications in their entireties are hereby cited to more fully describe the state of the art to which this invention pertains.

5

BACKGROUND OF THE INVENTIONsiRNAs and RNA interference

[0002] RNA interference (RNAi) is a phenomenon involving double-stranded (ds) RNA-dependent gene specific post-transcriptional silencing. Originally, attempts to study this phenomenon and to manipulate mammalian cells experimentally were frustrated by an active, non-specific antiviral defense mechanism which was activated in response to long dsRNA molecules; see Gil et al. 2000, *Apoptosis*, 5:107-114. Later it was discovered that synthetic duplexes of 21 nucleotide RNAs could mediate gene specific RNAi in mammalian cells, without the stimulation of the generic antiviral defence mechanisms (see Elbashir et al. *Nature* 2001, 411:494-498 and Caplen et al. *Proc Natl Acad Sci* 2001, 98:9742-9747). As a result, small interfering RNAs (siRNAs), which are short double-stranded RNAs, have become powerful tools in attempting to understand gene function.

[0003] Thus, RNA interference (RNAi) refers to the process of sequence-specific post-transcriptional gene silencing in mammals mediated by small interfering RNAs (siRNAs) (Fire et al, 1998, *Nature* 391, 806) or microRNAs (miRNAs) (Ambros V. *Nature* 431:7006,350-355(2004); and Bartel DP. *Cell*. 2004 Jan 23; 116(2): 281-97 *MicroRNAs: genomics, biogenesis, mechanism, and function*). The corresponding process in plants is commonly referred to as specific post-transcriptional gene silencing or RNA silencing and is also referred to as quelling in fungi. An siRNA is a double-stranded RNA molecule which down-regulates or silences (prevents) the expression of a gene/ mRNA of its endogenous (cellular) counterpart. RNA interference is based on the ability of dsRNA species to enter a specific protein complex, where it is then targeted to the complementary cellular RNA and specifically degrades it. Thus, the RNA interference response features an endonuclease complex containing an siRNA, commonly referred to as an RNA-induced silencing complex (RISC), which mediates cleavage of single-stranded RNA having a sequence complementary to the antisense strand of the siRNA duplex. Cleavage of the target RNA may take place in the middle of the region complementary to the antisense strand of the siRNA duplex (Elbashir et al 2001, *Genes Dev.*, 15, 188). In more detail, longer dsRNAs are digested into short (17-29 bp) dsRNA fragments (also referred to as short inhibitory RNAs - "siRNAs") by type III RNases (DICER, DROSHA, etc., Bernstein et al., *Nature*, 2001, v.409, p.363-6; Lee et al., *Nature*, 2003, 425, p.415-9). The RISC protein complex recognizes these fragments and complementary mRNA. The whole process is culminated by endonuclease cleavage of target mRNA (McManus&Sharp, *Nature Rev Genet*, 2002, v.3, p.737-47; Paddison &Hannon, *Curr Opin Mol Ther*. 2003 Jun; 5(3): 217-24). For information on these terms and proposed mechanisms, see Bernstein E., Denli AM. Hannon GJ: 2001 The rest is silence. *RNA*. I; 7(11): 1509-21; Nishikura K.: 2001 A short primer on RNAi: RNA-directed RNA polymerase acts as a key catalyst. *Cell*. I 16; 107(4): 415-8 and PCT publication WO 01/36646 (Glover et al.).

[0004] The selection and synthesis of siRNA corresponding to known genes has been widely reported; see for example Chalk AM, Wahlestedt C, Sonnhammer EL. 2004 Improved and automated prediction of effective siRNA *Biochem. Biophys. Res. Commun.* Jun 18; 319(1): 264-74; Sioud M, Leirdal M., 2004, Potential design rules and enzymatic synthesis of siRNAs, *Methods Mol Biol.*; 252:457-69; Levenkova N, Gu Q, Rux JJ. 2004, Gene specific siRNA selector *Bioinformatics*. I 12; 20(3): 430-2. and Ui-Tei K, Naito Y, Takahashi F, Haraguchi T, Ohki-Hamazaki H, Juni A, Ueda R, Saigo K., Guidelines for the selection of highly effective siRNA sequences for mammalian and chick RNA interference *Nucleic Acids Res.* 2004 I 9;32(3):936-48. See also Liu Y, Braasch DA, Nulf CJ, Corey DR. Efficient and isoform-selective inhibition of cellular gene expression by peptide nucleic acids, *Biochemistry*, 2004 I 24;43(7):1921-7. See also PCT publications WO 2004/015107 (Atugen) and WO 02/44321 (Tuschl et al), and also Chiu YL, Rana TM. siRNA function in RNAi: a chemical modification analysis, *RNA* 2003 Sep;9(9):1034-48 and I Patent Nos.5898031 and 6107094 (Crooke) for production of modified/ more stable siRNAs.

[0005] Several groups have described the development of DNA-based vectors capable of generating siRNA within cells. The method generally involves transcription of short hairpin RNAs that are efficiently processed to form siRNAs within cells. Paddison et al. *PNAS* 2002, 99:1443-1448; Paddison et al. *Genes & Dev* 2002, 16:948-958; Sui et al. *PNAS* 2002, 8:5515-5520; and Brummelkamp et al. *Science* 2002, 296:550-553. These reports describe methods to generate siRNAs capable of specifically targeting numerous endogenously and exogenously expressed genes.

[0006] siRNA has recently been successfully used for inhibition in primates; for further details see Tolentino et al., *Retina* 24(1) February 2004 I 132-138.

The p53 gene and polypeptide

[0007] The human p53 gene is a well-known and highly studied gene. The p53 polypeptide plays a key role in cellular stress response mechanisms by converting a variety of different stimuli, for example DNA damaging conditions, such as gamma-irradiation, deregulation of transcription or replication, and oncogene transformation, into cell growth arrest or apoptosis (Gottlieb et al, 1996, *Biochem. Biophys. Acta*, 1287, p.77). The p53 polypeptide is essential for the induction of programmed cell death or "apoptosis" as a response to such stimuli. Most anti-cancer therapies damage or kill also normal cells that contain native p53, causing severe side effects associated with the damage or death of healthy cells. Since such side effects are to a great extent determined by p53-mediated death of normal cells, the temporary suppression of p53 during the acute phase of anti-cancer therapy has been suggested as a therapeutic strategy to avoid these severe toxic events. This was described in US Patent No. 6,593,353 and in Komarov PG et al, 1999, A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy., *Science*, 285(5434):1651, 1653. p53 has been shown to be involved in chemotherapy and radiation-induced alopecia.(Botcharev et al, 2000, p53 is essential for Chemotherapy -induced Hair Loss, *Cancer Research*, 60, 5002-5006).

Alopecia

[0008] Recently there have been dramatic advances in the understanding of the molecules and pathways regulating hair follicle formation and hair growth. Chemotherapy disrupts the proliferation of matrix keratinocytes in the growth bulb that produce the hair shaft. This forces hair follicles to enter a dystrophic regression stage in which the integrity of the hair shaft is compromised and the hair then breaks and falls out. Because more than 90% of scalp follicles are in growth stage at any one time, these hairs are rapidly lost after chemotherapy, and thus the alopecia is rapid and extensive (George Cotsarelis and Sarah E. Millar, 2001, Towards a molecular understanding of hair loss and its treatment, *TRENDS in Molecular Medicine* Vol.7 No.7). Chemotherapy drugs most likely to cause hair loss are: Cisplatin, Cytarabine, Cyclophosphamide, Doxorubicin, Epirubicin, Etoposide, Ifosfamide and Vincristine. Radiation induced general alopecia is observed in virtually 100% of patients who receive whole brain radiation (WBR), particularly of 3000 rad and above.

[0009] Hair loss is one of the most feared side effects of chemotherapy among patients with cancer, even although hair lost following chemotherapy does eventually re-grow. From the patient's perspective, hair loss (alopecia) ranks second only to nausea as a distressing side effect of chemotherapy. About 75% of patients describe chemotherapy induced hair loss as equal to or more devastating than the pain caused by cancer.

[0010] Thus, although hair disorders are not life threatening, their profound impact on social interactions and on the psychological well-being of patients is undeniable. The demand for treatments for hair loss fuels a multi-billion dollar industry. Despite this, most currently marketed products are ineffective, evidenced by the fact that the FDA has approved only two treatments for hair loss. None of the known therapies or remedies is effective on cancer therapy-induced alopecia.

Acute renal failure (ARF).

[0011] ARF is a clinical syndrome characterized by rapid deterioration of renal function that occurs within days. The principal feature of ARF is an abrupt decline in glomerular filtration rate (GFR), resulting in the retention of nitrogenous wastes (urea, creatinine). In the general world population 170-200 cases of severe ARF per million population occur annually. To date, there is no specific treatment for established ARF. Several drugs have been found to ameliorate toxic and ischemic experimental ARF, as manifested by lower serum creatinine levels, reduced histological damage and faster recovery of renal function in different animal models. These include anti-oxidants, calcium channel blockers, diuretics, vasoactive substances, growth factors, anti-inflammatory agents and more. However, those drugs that have been studied in clinical trials showed no benefit, and their use in clinical ARF has not been approved.

[0012] In the majority of hospitalized patients, ARF is caused by acute tubular necrosis (ATN), which results from ischemic and/or nephrotoxic insults. Renal hypoperfusion is caused by hypovolemic, cardiogenic and septic shock, by administration of vasoconstrictive drugs or renovascular injury. Nephrotoxins include exogenous toxins such as contrast media and aminoglycosides as well as endogenous toxin such as myoglobin. Recent studies, however, support that apoptosis in renal tissues is prominent in most human cases of ARF. The principal site of apoptotic cell death is the distal nephron. During the initial phase of ischemic injury, loss of integrity of the actin cytoskeleton leads to flattening of the epithelium, with loss of the brush border, loss of focal cell contacts, and subsequent disengagement of the cell from the underlying substratum. It has been suggested that apoptotic tubule cell death may be more predictive of functional changes than necrotic cell death (Komarov et al. *Science*. 1999 Sep 10;285(5434):1733-7); see also (Supavekin et al. *Kidney Int.* 2003 May;63(5):1714-24).

[0013] WO03/064625 discloses siRNA compounds that target p53; none of these compounds however is very efficient as none of them showed complete down-regulation of the p53 gene, even when tested at concentration of 50 nM.

[0014] In conclusion, currently there are no satisfactory modes of therapy for the prevention and/or treatment of toxic

alopecia and of acute renal failure, nor are there a satisfactory mode of therapy for many other diseases and disorders which are accompanied by an elevated level of p53 polypeptide, and there is a need therefore to develop novel compounds for this purpose.

5 **SUMMARY OF THE INVENTION**

[0015] The invention provides novel double stranded oligoribonucleotides that inhibit the p53 gene, namely double-stranded siRNA compounds having the structure:

10 5' ugaaggugaaaaauucuc - Z 3' (antisense strand SEQ ID NO:48)
 3' Z'-acuucccacuuuaagag (sense strand SEQ ID NO:25);

wherein each a, c, u and g is a ribonucleotide and each consecutive ribonucleotide is joined to the next ribonucleotide by a covalent bond ; and

15 wherein each of Z and Z' may be present or absent, but if present is dTdT and is covalently attached at the 3' terminus of the strand in which it is present; and wherein alternating ribonucleotides in both the antisense strand and the sense strand are modified in their sugar residue such that a 2'-O-Methyl group is present and 2'-O-Methyl sugar modified ribonucleotides are present at the 5' terminus and the 3' terminus of the antisense strand and unmodified ribonucleotides are present at the 5' terminus and the 3' terminus of the sense strand. The description also discloses a pharmaceutical 20 composition comprising one or more such oligoribonucleotides, and a vector capable of expressing the oligoribonucleotide. The present invention also provides said oligoribonucleotides for use in a method of treating a patient suffering from a disease in which temporary (reversible) inhibition of p53 activity is beneficial comprising administering to the patient one or more oligoribonucleotides typically as a pharmaceutical composition, in a therapeutically effective dose so as to thereby treat the patient. The present invention also contemplates said oligoribonucleotides for use in treating 25 other disorders which are accompanied by an elevated level of p53 polypeptide. Since long-term p53 inactivation can significantly increase the risk of cancer, it is preferred that the inhibition of p53 using the molecules of the present invention will be temporary.

[0016] In one preferred embodiment, the novel siRNA molecules disclosed herein may be used in the treatment of tumors in cases where temporary suppression of p53 using the p53 siRNA would be beneficial along with conventional chemotherapy (as described herein) or radiotherapy. For example, the novel siRNA molecules disclosed herein would protect normal p53-containing cells from chemotherapy or radiotherapy-induced apoptosis. The novel siRNA molecules disclosed herein may also be used for inhibition of p53 expression in specific cancer cells in cases where p53 inhibition potentiates apoptotic cell death in these cells. Specifically, radiation therapy and chemotherapy may cause severe side effects, such as severe damage to the lymphoid and hematopoietic system and intestinal epithelia, which limit the 35 effectiveness of these therapies, and may cause hair loss which causes psychological distress. These side effects are caused by p53-mediated apoptosis. Therefore, to eliminate or reduce adverse side effects associated with cancer treatment, it would be beneficial to induce temporary inhibition of p53 activity in normal cells using the siRNA molecules of the present invention, thereby protecting normal tissue.

[0017] In another preferred embodiment, the novel siRNA molecules disclosed herein may be used in the treatment 40 of acute renal failure (ARF), which is characterized by rapid deterioration of renal function associated with apoptotic cell death in the renal tissue.

[0018] The novel siRNA molecules disclosed herein may also be used in other conditions in which p53 is activated as a consequence of a variety of stresses associated with injuries such as a burn, hyperthermia, hypoxia associated with a blocked blood supply such as in myocardial infarction, stroke, and ischemia. Temporary p53 inhibition using the 45 siRNA molecules of the present invention can be therapeutically effective in reducing or eliminating p53-dependent neuronal death in the central nervous system, i.e., brain and spinal cord injury, the preservation of tissues and organs prior to transplanting, preparation of a host for a bone marrow transplant, and reducing or eliminating neuronal damage during a seizure.

[0019] p53 also plays a role in cell aging. In particular, morphological and physiological alterations of normal tissues 50 associated with aging may be related to p53 activity. Senescent cells that accumulate in tissues over time are known to maintain very high levels of p53-dependent transcription. p53-dependent secretion of growth inhibitors by senescent cells accumulate in aging tissue. Thus, the siRNA molecules disclosed herein may also be used in suppression of tissue aging.

55 **BRIEF DESCRIPTION OF THE FIGURES**

[0020]

Figure 1. This figure represents the nucleotide sequence of the human p53 gene- SEQ ID NO:1.

Figure 2. This figure represents the amino acid sequence of the human p53 polypeptide - SEQ ID NO:2.

5 Figure 3. This figure shows Western Blot results demonstrating the effect of various human p53 siRNAs on p53 expression.

Figure 4. This figure shows Western Blot results demonstrating the effect of various mouse p53 siRNAs on p53 expression.

10

Figure 5. This figure shows the level of serum creatinine as an indication for acute renal failure in animals that underwent bilateral kidney arterial clamp and were treated with p53 siRNA compound or a control, as indicated.

15 Figure 6. This figure shows the extent of tubular necrosis in renal tissue in animals that underwent bilateral kidney arterial clamp and were treated with the p53 siRNA compound.

Figure 7. This figure demonstrates that p53 siRNA treatment down-regulated the expression of the pro-apoptotic gene Puma in the cortical compartment of the kidney in animal subjected to ischemia-reperfusion kidney injury.

20

DETAILED DESCRIPTION OF THE INVENTION

[0021] The present invention relates generally to compounds which down-regulate expression of the p53 gene particularly to novel small interfering RNAs (siRNAs), and to the use of these novel siRNAs in the treatment of various diseases and medical conditions in particular alopecia or acute renal failure or a disorder accompanied by an elevated level of p53 polypeptide. The double-stranded siRNA compounds of the invention have the structure:

30 5' ugaaggugaaaaauucuc - Z 3' (antisense strand SEQ ID NO:48)
 3' Z'-acuuccccacuuuaagag (sense strand SEQ ID NO:25);

wherein each a, c, u and g is a ribonucleotide and each consecutive ribonucleotide is joined to the next ribonucleotide by a covalent bond ; and
 wherein each of Z and Z' may be present or absent, but if present is dTdT and is covalently attached at the 3' terminus 35 of the strand in which it is present; and
 wherein alternating ribonucleotides in both the antisense strand and the sense strand are modified in their sugar residue such that a 2'-O-Methyl group is present and 2'-O-Methyl sugar modified ribonucleotides are present at the 5' terminus and the 3' terminus of the antisense strand and unmodified ribonucleotides are present at the 5' terminus and the 3' terminus of the sense strand.

40 **[0022]** The inventors of the present invention have found that it is beneficial to induce temporary inhibition of p53 in order to treat any of said diseases or disorders.

[0023] The present invention provides methods and compositions for inhibiting expression of a target p53 gene *in vivo*. In general, the method includes administering small interfering RNAs (i.e., siRNAs) of the invention that are targeted to a particular p53 mRNA and hybridize to, or interact with, the mRNAs under biological conditions (within the cell), or 45 a nucleic acid material that can produce siRNA in a cell, in an amount sufficient to down-regulate expression of a target gene by an RNA interference mechanism. In particular, the subject method can be used to inhibit expression of the p53 gene for treatment of a disease.

50 **[0024]** In accordance with the present invention, the siRNA molecules or inhibitors of the p53 gene may be used as drugs to treat various pathologies in particular alopecia or acute renal failure or other disorders accompanied by an elevated level of p53 polypeptide. Since long-term p53 inactivation can significantly increase the risk of cancer, it is preferred that the inhibition of p53 using the molecules of the present invention be temporary / reversible.

[0025] The present invention provides double-stranded oligoribonucleotides (siRNAs), which down-regulate the expression of the p53 gene. An siRNA of the invention is a duplex oligoribonucleotide in which the sense strand is derived from the mRNA sequence of the p53 gene, and the antisense strand is complementary to the sense strand. In general, 55 some deviation from the target mRNA sequence is tolerated without compromising the siRNA activity (see e.g. Czauderna et al 2003 Nucleic Acids Research 31(11), 2705-2716). An siRNA of the invention inhibits gene expression on a post-transcriptional level with or without destroying the mRNA. Without being bound by theory, siRNA may target the mRNA for specific cleavage and degradation and/ or may inhibit translation from the targeted message.

[0026] There are at least four variant p53 polypeptides (see Bourdon et al. *Genes Dev.* 2005; 19: 2122-2137). The sequence given in Figure 1 is the nucleotide sequence of gi-8400737. The corresponding polypeptide sequence has 393 amino acids; see Figure 2. All variants and any other similar minor variants are included in the definition of p53 polypeptide and in the definition of the p53 genes encoding them.

[0027] As used herein, the term "p53 gene" is defined as any homolog of the p53 gene having preferably 90% homology, more preferably 95% homology, and even more preferably 98% homology to the amino acid encoding region of SEQ ID NO:1 or nucleic acid sequences which bind to the p53 gene under conditions of highly stringent hybridization, which are well-known in the art (for example, see Ausubel et al., *Current Protocols in Molecular Biology*, John Wiley and Sons, Baltimore, Maryland (1988), updated in 1995 and 1998).

[0028] As used herein, the term "p53", or "p53 polypeptide" is defined as any homolog of the p53 polypeptide having preferably 90% homology, more preferably 95% homology, and even more preferably 98% homology to SEQ ID NO:2, as either full-length or a fragment or a domain thereof, as a mutant or the polypeptide encoded by a spliced variant nucleic acid sequence, as a chimera with other polypeptides, provided that any of the above has the same or substantially the same biological function as the p53 polypeptide.

[0029] Generally, the siRNAs disclosed in the present description comprise a ribonucleic acid comprising a double stranded structure, whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second strand comprises a second stretch of contiguous nucleotides and whereby said second stretch is at least partially identical to a target nucleic acid, whereby said first strand and/or said second strand comprises a plurality of groups of modified nucleotides having a modification at the 2'-position whereby within the strand each group of modified nucleotides is flanked on one or both sides by a flanking group of nucleotides whereby the flanking nucleotides forming the flanking group of nucleotides is either an unmodified nucleotide or a nucleotide having a modification different from the modification of the modified nucleotides. Further, said first strand and/or said second strand may comprise said plurality of modified nucleotides and may comprises said plurality of groups of modified nucleotides.

[0030] The group of modified nucleotides and the group of flanking nucleotides comprises one nucleotide.

[0031] The pattern of modified nucleotides of said first strand is shifted by one nucleotide relative to the pattern of modified nucleotides of the second strand.

[0032] The modifications discussed above are methoxy modifications.

[0033] The double stranded structure of the siRNA may be blunt ended, on one or both sides. More specifically, the double stranded structure may be blunt ended on the double stranded structure's side which is defined by the 5'- end of the first strand and the 3'-end of the second strand, or the double stranded structure may be blunt ended on the double stranded structure's side which is defined by at the 3'-end of the first strand and the 5'-end of the second strand.


[0034] Additionally, at least one of the two strands may have an overhang of at least one nucleotide at the 5'-end; the overhang may consist of at least one deoxyribonucleotide. At least one of the strands may also optionally have an overhang of at least one nucleotide at the 3'-end.

[0035] The length of the double-stranded structure of the siRNA is typically 19 bases.

[0036] The first strand and the second strand may be linked by a loop structure, which may be comprised of a non-nucleic acid polymer such as, *inter alia*, polyethylene glycol. Alternatively, the loop structure may be comprised of a nucleic acid.

[0037] Further, the 5'-terminus of the first strand of the siRNA may be linked to the 3'-terminus of the second strand, or the 3'-end of the first strand may be linked to the 5'-terminus of the second strand, said linkage being via a nucleic acid linker typically having a length between 10-2000 nucleobases.

[0038] In particular, the invention provides a compound having structure A:



50 wherein each N and N' is a ribonucleotide which may be modified or unmodified in its sugar residue and (N)_x and (N')_y is oligomer in which each consecutive N or N' is joined to the next N or N' by a covalent bond ;
 wherein each of x and y is 19;

wherein each of Z and Z' may be present or absent, but if present is dTdT and is covalently attached at the 3' terminus of the strand in which it is present;

and wherein the sequence of (N)_x is SEQ ID NO:48 and (N')_y is SEQ ID NO:25.

55 [0039] It will be readily understood by those skilled in the art that the compounds of the present invention consist of a plurality of nucleotides, which are linked through covalent linkages. Each such covalent linkage may be a phosphodiester linkage, a phosphothioate linkage, or a combination of both, along the length of the nucleotide sequence of the individual strand. Other possible backbone modifications are described *inter alia* in U.S. Patent Nos. 5,587,361; 6,242,589;

6,277,967; 6,326,358; 5,399,676; 5,489,677; and 5,596,086.

[0040] According to the invention $x = y = 19$.

[0041] In one embodiment of the compound of the invention, Z and Z' are both absent; in another embodiment one of Z or Z' is present.

5 [0042] In the invention, alternating ribonucleotides are modified in both the antisense and the sense strands of the compound. In particular the siRNA has been such modified such that a 2' O-Me group was present on the first, third, fifth, seventh, ninth, eleventh, thirteenth, fifteenth, seventeenth and nineteenth nucleotide of the antisense strand, whereby the very same modification, i. e. a 2'-O-Me group was present at the second, fourth, sixth, eighth, tenth, twelfth, fourteenth, sixteenth and eighteenth nucleotide of the sense strand.

10 The sequence of the siRNA is that of I5 in Table A.

[0043] According to one preferred embodiment of the invention, the antisense and the sense strands of the siRNA molecule are both phosphorylated only at the 3'-terminus and not at the 5'-terminus. According to another preferred embodiment of the invention, the antisense and the sense strands are both non-phosphorylated both at the 3'-terminus and also at the 5'-terminus.

15 [0044] In the compound of the invention, the ribonucleotides at the 5' and 3' termini of the antisense strand are modified in their sugar residues, and the ribonucleotides at the 5' and 3' termini of the sense strand are unmodified in their sugar residues.

[0045] The description further discloses a vector capable of expressing any of the aforementioned oligoribonucleotides in unmodified form in a cell after which appropriate modification may be made.

20 [0046] The invention also provides a composition comprising one or more of the compounds of the invention in a carrier, preferably a pharmaceutically acceptable carrier. This composition may comprise a mixture of two or more different siRNAs.

25 [0047] The invention also provides a composition which comprises the above compound of the invention covalently or non-covalently bound to one or more compounds of the invention in an amount effective to inhibit human p53 and a carrier. This composition may be processed intracellularly by endogenous cellular complexes to produce one or more oligoribonucleotides of the invention.

[0048] The invention also provides a composition comprising a carrier and one or more of the compounds of the invention in an amount effective to down-regulate expression in a cell of a human p53, which compound comprises a sequence substantially complementary to the sequence of $(N)_x$.

30 [0049] Additionally the description discloses a method of down-regulating the expression of gene p53 by at least 50% as compared to a control comprising contacting an mRNA transcript of gene p53 with one or more of the compounds of the invention.

[0050] In one embodiment the oligoribonucleotide is down-regulating p53, whereby the down-regulation of p53 is selected from the group comprising down-regulation of p53 function, down-regulation of p53 polypeptide and down-regulation of p53 mRNA expression.

35 [0051] In one embodiment the compound is down-regulating a p53 polypeptide, whereby the down-regulation of p53 is selected from the group comprising down-regulation of p53 function (which may be examined by an enzymatic assay or a binding assay with a known interactor of the native gene / polypeptide, *inter alia*), down-regulation of p53 protein (which may be examined by Western blotting, ELISA or immuno-precipitation, *inter alia*) and down-regulation of p53 mRNA expression (which may be examined by Northern blotting, quantitative RT-PCR, in-situ hybridisation or microarray hybridisation, *inter alia*).

40 [0052] The invention also provides a composition of the invention for use in a method of treating a patient suffering from a disease accompanied by an elevated level of p53 polypeptide, the method comprising administering to the patient a composition of the invention in a therapeutically effective dose thereby treating the patient. Preferably, the present invention provides said use in a method of treating a patient suffering from a disease in which temporary inhibition of p53 is beneficial. In one preferred embodiment, the compositions of the present invention are used for the treatment of tumors along with the conventional chemotherapy or radiotherapy in order to prevent the alopecia associated with chemotherapy or radiotherapy. In another preferred embodiment, the compositions of the present invention are used for the treatment of acute renal failure. In yet another preferred embodiment, the compositions of the present invention are used in conditions in which p53 is activated as a consequence of a variety of stresses associated with injuries such as a burn, hyperthermia, hypoxia associated with a blocked blood supply such as in myocardial infarction, stroke, and ischemia. Temporary p53 inhibition using the siRNA molecules of the present invention can be therapeutically effective in reducing or eliminating p53-dependent neuronal death in the central nervous system, i.e., brain and spinal cord injury, in preserving of tissue and an organ prior to transplanting, preparation of a host for a bone marrow transplant, reducing or eliminating neuronal damage during a seizure and in suppressing tissue aging.

45 [0053] The invention also provides a therapeutically effective dose of one or more compounds of the invention for use in the treatment of a disease accompanied by an elevated level of p53 polypeptide, such as in a patient suffering from alopecia or acute renal failure.

[0054] More particularly, the description discloses an oligoribonucleotide wherein one strand comprises consecutive nucleotides having, from 5' to 3', the sequence set forth in SEQ ID NOS: 3-25 (Table A, sense strands) or in SEQ ID NOS: 49-119 (Table B, sense strands) or in SEQ ID NOS: 191-253 (Table C, sense strands) or a homolog thereof wherein in up to 2 of the nucleotides in each terminal region a base is altered.

5 [0055] The terminal region of the oligonucleotide refers to bases 1-4 and/or 16-19 in the 19-mer sequence and to bases 1-4 and/or 18-21 in the 21-mer sequence.

[0056] Additionally, the description discloses oligoribonucleotides wherein one strand comprises consecutive nucleotides having, from 5' to 3', the sequence set forth SEQ ID NOS: 26-48 (Table A, antisense strands) or SEQ ID NOS: 120-190 (Table B, antisense strands) or SEQ ID NOS: 254-316 (Table C, antisense strands) or a homolog thereof 10 wherein in up to 2 of the nucleotides in each terminal region a base is altered.

[0057] The preferred oligonucleotides of the description are human p53 oligonucleotides serial numbers 3, 5, 20 and 15 23 in Table D and mouse p53 oligonucleotides serial numbers 11, 12, 14, 17 and 18 in Table E. These are identical to serial numbers 3, 5, 20 and 23 (human) and also 11, 12, 14, 17 and 18 (mouse) in Table A. The oligonucleotides of the invention are human p53 oligonucleotides having the sequence of serial number 23 in Table A.

20 [0058] The presently most preferred compound of the invention is a blunt-ended 19-mer oligonucleotide, i.e. x=y=19 and Z and Z' are both absent. The oligonucleotide molecule is either phosphorylated at 3' termini of both sense and anti-sense strands, or non-phosphorylated at all; or having 1st nucleotide in the 5' position on the sense strand specifically modified to abolish any possibility of in vivo 5'-phosphorylation. The alternating ribonucleotides are modified at the 2' position in both the antisense and the sense strands, wherein the moiety at the 2' position is methoxy (2'-O-methyl) and 25 wherein the ribonucleotides at the 5' and 3' termini of the antisense strand are modified in their sugar residues, and the ribonucleotides at the 5' and 3' termini of the sense strand are unmodified in their sugar residues. The presently most preferred such compounds are such modified oligonucleotides comprising the sequences having serial number 23 in Table A.

30 [0059] Delivery: Delivery systems aimed specifically at the enhanced and improved delivery of siRNA into mammalian cells have been developed, see, for example, Shen et al (FEBS letters 539: 111-114 (2003)), Xia et al., Nature Biotechnology 20: 1006-1010 (2002), Reich et al., Molecular Vision 9: 210-216 (2003), Sorensen et al. (J.Mol.Biol. 327: 761-766 (2003), Lewis et al., Nature Genetics 32: 107-108 (2002) and Simeoni et al., Nucleic Acids Research 31, 11: 2717-2724 (2003). siRNA has recently been successfully used for inhibition in primates; for further details see Tolentino et al., Retina 24(1) February 2004 | 132-138. Respiratory formulations for siRNA are described in U.S. patent application No. 2004/0063654 of Davis et al. Cholesterol-conjugated siRNAs (and other steroid and lipid conjugated siRNAs) can be used for delivery see Soutschek et al Nature 432: 173-177(2004) *Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs*; and Lorenz et al. Bioorg. Med. Chemistry. Lett. 14:4975-4977 (2004) *Steroid and lipid conjugates of siRNAs to enhance cellular uptake and gene silencing in liver cells*.

35 [0060] The siRNAs or pharmaceutical compositions of the present invention are administered and dosed in accordance with good medical practice, taking into account the clinical condition of the individual patient, the disease to be treated, the site and method of administration, scheduling of administration, patient age, sex, body weight and other factors known to medical practitioners.

40 [0061] The "therapeutically effective dose" for purposes herein is thus determined by such considerations as are known in the art. The dose must be effective to achieve improvement including but not limited to improved survival rate or more rapid recovery, or improvement or elimination of symptoms and other indicators as are selected as appropriate measures by those skilled in the art. The compounds of the present invention can be administered by any of the conventional routes of administration. It should be noted that the compound can be administered as the compound or as pharmaceutically acceptable salt and can be administered alone or as an active ingredient in combination with pharmaceutically acceptable carriers, solvents, diluents, excipients, adjuvants and vehicles. The compounds can be administered orally, 45 subcutaneously or parenterally including intravenous, intraarterial, intramuscular, intraperitoneally, and intranasal administration as well as intrathecal and infusion techniques. Implants of the compounds are also useful. Liquid forms may be prepared for injection, the term including subcutaneous, transdermal, intravenous, intramuscular, intrathecal, and other parenteral routes of administration. The liquid compositions include aqueous solutions, with and without organic co-solvents, aqueous or oil suspensions, emulsions with edible oils, as well as similar pharmaceutical vehicles. In addition, 50 under certain circumstances the compositions for use in the novel treatments of the present invention may be formed as aerosols, for intranasal and like administration. The patient being treated is a warm-blooded animal and, in particular, mammals including man. The pharmaceutically acceptable carriers, solvents, diluents, excipients, adjuvants and vehicles as well as implant carriers generally refer to inert, non-toxic solid or liquid fillers, diluents or encapsulating material not reacting with the active ingredients of the invention and they include liposomes and microspheres. Examples of delivery 55 systems useful in the present invention include U. S. Patent Nos. 5,225,182; 5,169,383; 5,167,616; 4,959,217; 4,925,678; 4,487,603; 4,486,194; 4,447,233; 4,447,224; 4,439,196; and 4,475,196. Many other such implants, delivery systems, and modules are well known to those skilled in the art. In one specific embodiment of this invention topical and transdermal formulations are particularly preferred.

[0062] In general, the active dose of compound for humans is in the range of from 1ng/kg to about 20-100 mg/kg body weight per day, preferably about 0.01 mg to about 2-10 mg/kg body weight per day, in a regimen of one dose per day or twice or three or more times per day for a period of 1-4 weeks or longer.

[0063] It is noted that the delivery of the siRNA compounds according to the present invention to the target cells in the kidney proximal tubules is particularly effective in the treatment of acute renal failure. Without being bound by theory, this may be due to the fact that normally siRNA molecules are excreted from the body via the cells of the kidney proximal tubules. Thus, naked siRNA molecules are naturally concentrated in the cells that are targeted for the therapy in acute renal failure.

[0064] The term "treatment" as used herein refers to administration of a therapeutic substance effective to ameliorate symptoms associated with a disease, to lessen the severity or cure the disease, or to prevent the disease from occurring.

[0065] In a particular embodiment, the administration comprises intravenous administration. In another particular embodiment the administration comprises topical or local administration. Another aspect of the invention is a pharmaceutical composition of the invention for use in a method of treating a patient suffering from alopecia or acute renal failure or a disorder which is accompanied by an elevated level of p53 polypeptide, comprising administering to the patient said pharmaceutical composition of the invention in a therapeutically effective amount so as to thereby treat the patient.

[0066] In a preferred embodiment for treatment of alopecia, the administration comprises topical or local administration. In another preferred embodiment the administration comprises transdermal administration. In a particular embodiment the pharmaceutical composition is applied to the scalp of the patient. In a preferred embodiment for treatment of ARF, the administration comprises intravenous, intra-arterial or intra-peritoneal administration.

[0067] Another aspect of the invention is a pharmaceutical composition of the invention for use in a method of preventing alopecia in a patient undergoing treatment which causes alopecia, comprising administering to the patient said pharmaceutical composition of the invention in a therapeutically effective amount so as to thereby treat the patient.

[0068] In another aspect of the invention a pharmaceutical composition is provided which comprises any of the above oligoribonucleotides of the invention and a pharmaceutically acceptable carrier. Another aspect of the invention is the use of a therapeutically effective amount of any of the above oligoribonucleotides of the invention for the preparation of a medicament for promoting recovery in a patient suffering from alopecia or acute renal failure or a disorder which is accompanied by an elevated level of p53.

[0069] In a preferred embodiment, the medicament comprises a topical medicament. In a particular embodiment the medicament is applied to the scalp of the patient. In another preferred embodiment the medicament comprises transdermal administration.

[0070] In all the above aspects of the invention the alopecia may be induced by chemotherapy or by radiotherapy and is then termed "toxic alopecia". In more detail, toxic alopecia may be caused by irradiation such as gamma irradiation or by chemotherapeutic agents such as etoposide, 5-FU (5-fluorouracil), cis-platinum, doxorubicin, a vinca alkaloid, vincristine, vinblastine, vinorelbine, taxol, cyclophosphamide, ifosfamide, chlorambucil, busulfan, mechlorethamine, mitomycin, dacarbazine, carboplatinum, thiotepa, daunorubicin, idarubicin, mitoxantrone, bleomycin, esperamicin A1, dactinomycin, plicamycin, carmustine, lomustine, temozolamide, streptozocin, melphalan, dactinomycin, procarbazine, dexamethasone, prednisone, 2-chlorodeoxyadenosine, cytarabine, docetaxel, fludarabine, gemcitabine, herceptin, hydroxyurea, irinotecan, methotrexate, oxaliplatin, rituximab, semustine, epirubicin, etoposide, tomudex and topotecan, or a chemical analog of one of these chemotherapeutic agents. The chemotherapeutic agents most likely to cause hair loss are: cis-platinum, cytarabine, cyclophosphamide, doxorubicin, epirubicin, etoposide, ifosfamide and vincristine.

[0071] The compounds of the invention are preferably used for treating acute renal failure, in particular acute renal failure due to ischemia in post surgical patients, and acute renal failure due to chemotherapy treatment such as cisplatin administration or sepsis- associated acute renal failure. A preferred use of the compounds of the invention is for the prevention of acute renal failure in high-risk patients undergoing major cardiac surgery or vascular surgery. The patients at high-risk of developing acute renal failure can be identified using various scoring methods such as the Cleveland Clinic algorithm or that developed by US Academic Hospitals (QMMI) and by Veterans' Administration (CICSS). Other preferred uses of the compounds of the invention are for the prevention of ischemic acute renal failure in kidney transplant patients or for the prevention of toxic acute renal failure in patients receiving chemotherapy. Other uses are for wound healing, acute liver failure, cisplatin-induced deafness (perhaps topically), ex vivo expansion of hematopoietic stem cells, preservation of donor organs/tissues before transplantation by soaking in siRNA solution (perhaps by electroporation) and subsequent improvement of graft tissue survival following transplantation. Other indications may be stroke, Parkinson's disease, Alzheimer's disease, doxorubicin-induced cardiotoxicity, myocardial infarction/heart failure and improvement of graft tissue survival following transplantation (by systemic administration). Without being bound by theory all these disorders are accompanied by an elevated level of p53 polypeptide.

[0072] The present description also provides for a process of preparing a pharmaceutical composition, which comprises:

obtaining one or more double stranded compound of the invention ; and

admixing said compound with a pharmaceutically acceptable carrier.

[0073] The present description also provides for a process of preparing a pharmaceutical composition, which comprises admixing one or more compounds of the present invention with a pharmaceutically acceptable carrier.

[0074] In a preferred embodiment, the compound used in the preparation of a pharmaceutical composition is admixed with a carrier in a pharmaceutically effective dose. In a particular embodiment the compound of the present invention is conjugated to a steroid or to a lipid or to another suitable molecule e.g. to cholesterol.

[0075] Modifications or analogs of nucleotides can be introduced to improve the therapeutic properties of the nucleotides. Improved properties include increased nuclease resistance and/or increased ability to permeate cell membranes.

[0076] Accordingly, the present description also includes all analogs of, or modifications to, a oligonucleotide of the invention that does not substantially affect the function of the polynucleotide or oligonucleotide. In a preferred embodiment such modification is related to the base moiety of the nucleotide, to the sugar moiety of the nucleotide and/or to the phosphate moiety of the nucleotide.

[0077] In embodiments of the description, the nucleotides can be selected from naturally occurring or synthetically modified bases. Naturally occurring bases include adenine, guanine, cytosine, thymine and uracil. Modified bases of the oligonucleotides include inosine, xanthine, hypoxanthine, 2-aminoadenine, 6-methyl-, 2-propyl- and other alkyladenines, 5-halo uracil, 5-halo cytosine, 6-aza cytosine and 6-aza thymine, pseudo uracil, 4-thiuracil, 8-halo adenine, 8-aminoadenine, 8-thiol adenine, 8-thiolalkyl adenine, 8-hydroxyl adenine and other 8-substituted adenines, 8-halo guanine, 8-amino guanine, 8-thiol guanine, 8-thioalkyl guanine, 8-hydroxyl guanine and other substituted guanines, other aza and deaza adenines, other aza and deaza guanines, 5-trifluoromethyl uracil and 5-trifluoro cytosine.

[0078] In addition, analogs of nucleotides can be prepared wherein the structures of the nucleotides are fundamentally altered and are better suited as therapeutic or experimental reagents. An example of a nucleotide analog is a peptide nucleic acid (PNA) wherein the deoxyribose (or ribose) phosphate backbone in DNA (or RNA) is replaced with a polyamide backbone similar to that found in peptides. PNA analogs have been shown to be resistant to degradation by enzymes and to have extended *lives in vivo and in vitro*. Further, PNAs have been shown to bind more strongly to a complementary DNA sequence than to a DNA molecule. This observation is attributed to the lack of charge repulsion between the PNA strand and the DNA strand. Other modifications that can be made to oligonucleotides include polymer backbones, cyclic backbones, or acyclic backbones.

[0079] In one embodiment the modification is a modification of the phosphate moiety, whereby the modified phosphate moiety is selected from the group comprising phosphothioate.

[0080] The compounds of the present invention can be synthesized by any of the methods that are well-known in the art for synthesis of ribonucleic (or deoxyribonucleic) oligonucleotides. Such synthesis is, among others, described in Beaucage S.L. and Iyer R.P., Tetrahedron 1992; 48: 2223-2311, Beaucage S.L. and Iyer R.P., Tetrahedron 1993; 49: 6123-6194 and Caruthers M.H. et. al., Methods Enzymol. 1987; 154: 287-313; the synthesis of thioates is, among others, described in Eckstein F., Annu. Rev. Biochem. 1985; 54: 367-402, the synthesis of RNA molecules is described in Sproat B., in Humana Press 2005 edited by Herdewijn P.; Kap. 2: 17-31 and respective downstream processes are, among others, described in Pingoud A. et. al., in IRL Press 1989 edited by Oliver R.W.A.; Kap. 7: 183-208 and Sproat B., in Humana Press 2005 edited by Herdewijn P.; Kap. 2: 17-31 (supra).

[0081] Other synthetic procedures are known in the art e.g. the procedures as described in Usman et al., 1987, J. Am. Chem. Soc., 109, 7845; Scaringe et al., 1990, Nucleic Acids Res., 18, 5433; Wincott et al., 1995, Nucleic Acids Res. 23, 2677-2684; and Wincott et al., 1997, Methods Mol. Bio., 74, 59, and these procedures may make use of common nucleic acid protecting and coupling groups, such as dimethoxytrityl at the 5'-end, and phosphoramidites at the 3'-end. The modified (e.g. 2'-O-methylated) nucleotides and unmodified nucleotides are incorporated as desired.

[0082] The oligonucleotides of the present invention can be synthesized separately and joined together post-synthetically, for example, by ligation (Moore et al., 1992, Science 256, 9923; Draper et al., International PCT publication No. WO93/23569; Shabarova et al., 1991, Nucleic Acids Research, 19, 4247; Bellon et al., 1997, Nucleosides & Nucleotides, 16, 951; Bellon et al., 1997, Bioconjugate Chem. 8, 204), or by hybridization following synthesis and/or deprotection.

[0083] It is noted that a commercially available machine (available, *inter alia*, from Applied Biosystems) can be used; the oligonucleotides are prepared according to the sequences disclosed herein. Overlapping pairs of chemically synthesized fragments can be ligated using methods well known in the art (e.g., see U.S. Patent No. 6,121,426). The strands are synthesized separately and then are annealed to each other in the tube. Then, the double-stranded siRNAs are separated from the single-stranded oligonucleotides that were not annealed (e.g. because of the excess of one of them) by HPLC. In relation to the siRNAs or siRNA fragments of the present invention, two or more such sequences can be synthesized and linked together for use in the present invention.

[0084] The compounds of the invention can also be synthesized via a tandem synthesis methodology, as described in US patent application publication No. US2004/0019001 (McSwiggen), wherein both siRNA strands are synthesized as a single contiguous oligonucleotide fragment or strand separated by a cleavable linker which is subsequently cleaved to provide separate siRNA fragments or strands that hybridize and permit purification of the siRNA duplex. The linker

can be a polynucleotide linker or a non-nucleotide linker.

[0085] The present description further provides for a pharmaceutical composition comprising two or more siRNA molecules for the treatment of any of the diseases and conditions mentioned herein, whereby said two molecules may be physically mixed together in the pharmaceutical composition in amounts which generate equal or otherwise beneficial activity, or may be covalently or non-covalently bound, or joined together by a nucleic acid linker of a length ranging from 2-100, preferably 2-50 or 2-30 nucleotides. In one aspect, the siRNA molecules are comprised of a double-stranded nucleic acid structure as described herein, wherein the two siRNA sequences are selected from Tables A-C, preferably from Table A, ID Nos: 3, 5, 20 and 23 (human sequences) and 11,12,14,17 and 18 (mouse sequences).

[0086] In another aspect, the siRNA molecules are comprised of a double-stranded nucleic acid structure, wherein the first siRNA sequence is selected from Tables A-C, preferably from Table A, ID Nos: 3, 5, 20 and 23 (human p53 sequences) or 11, 12, 14, 17 and 18 (mouse p53 sequences) and the second siRNA molecule targets a pro-apoptotic gene, thereby providing beneficial activity. The tandem double-stranded structure which comprises two or more siRNA sequences is processed intracellularly to form two or more different siRNAs. Such second siRNA molecule is preferably an siRNA molecule that targets a pro-apoptotic gene.

[0087] The siRNA molecules are covalently or non-covalently bound or joined by a linker to form a tandem siRNA molecule. Such tandem siRNA molecules comprising two siRNA sequences are typically of 38-150 nucleotides in length, more preferably 38 or 40-60 nucleotides in length, and longer accordingly if more than two siRNA sequences are included in the tandem molecule. A longer tandem molecule comprised of two or more longer sequences which encode siRNA produced via internal cellular processing, e.g., long dsRNAs, is also envisaged, as is a tandem molecule encoding two or more shRNAs. Such tandem molecules are also considered to be a part of the present invention.

[0088] siRNA molecules that target p53 may be the main active component in a pharmaceutical composition, or may be one active component of a pharmaceutical composition containing two or more siRNAs (or molecules which encode or endogenously produce two or more siRNAs, be it a mixture of molecules or one or more tandem molecules which encode two or more siRNAs), said pharmaceutical composition further being comprised of one or more additional siRNA molecule which targets one or more additional gene. Simultaneous inhibition of p53 and said additional gene(s) will likely have an additive or synergistic effect for treatment of the diseases disclosed herein.

[0089] In a specific example, the pharmaceutical composition for treatment of the diseases disclosed herein may be comprised of the following compound combinations: 1) p53 siRNA and Fas siRNA; 2) p53 siRNA and Bax siRNA; 3) p53 siRNA and Noxa siRNA; 4) p53 siRNA and Puma siRNA; 5) p53 siRNA and RTP801 siRNA; 6) p53 siRNA and PIDD siRNA; 7) p53 siRNA, Fas siRNA and any of RTP801 siRNA, Bax siRNA, Noxa siRNA or Puma siRNA or PIDD siRNA to form trimers or polymers (i.e., tandem molecules which encode three siRNAs). Other preferred options of pro-apoptotic genes to be combined with the p53 siRNA are TNF α , caspase 2, caspase 3, caspase 9, E2F1, and PARP-1. A preferred combination according to the present invention is p53 siRNA and RTP801 siRNA.(see PCT patent application PCT/EP 2005/008891).

[0090] Additionally, p53 siRNA or any nucleic acid molecule comprising or encoding p53 siRNA can be linked (covalently or non-covalently) to antibodies against cell surface internalizable molecules expressed on the target cells, in order to achieve enhanced targeting for treatment of the diseases disclosed herein. For example, anti-Fas antibody (preferably a neutralizing antibody) may be combined with a p53 siRNA molecule.

[0091] The compounds of the present invention can be delivered either directly or with viral or non-viral vectors. When delivered directly the sequences are generally rendered nuclease resistant. Alternatively the sequences can be incorporated into expression cassettes or constructs such that the sequence is expressed in the cell as discussed herein below. Generally the construct contains the proper regulatory sequence or promoter to allow the sequence to be expressed in the targeted cell. Vectors optionally used for delivery of the compounds of the present invention are commercially available, and may be modified for the purpose of delivery of the compounds of the present invention by methods known to one of skill in the art.

[0092] It is also envisaged that a long oligonucleotide (typically 25-500 nucleotides in length) comprising one or more stem and loop structures, where stem regions comprise the sequences of the oligonucleotides of the invention, may be delivered in a carrier, preferably a pharmaceutically acceptable carrier, and may be processed intracellularly by endogenous cellular complexes (e.g. by DROSHA and DICER as described above) to produce one or more smaller double stranded oligonucleotides (siRNAs) which are oligonucleotides of the invention. This oligonucleotide can be termed a tandem shRNA construct. It is envisaged that this long oligonucleotide is a single stranded oligonucleotide comprising one or more stem and loop structures, wherein each stem region comprises a sense and corresponding antisense siRNA sequence of an p53 gene. In particular, it is envisaged that this oligonucleotide comprises sense and antisense siRNA sequences as depicted in any one of Tables A, B or C.

[0093] As used herein, the term "polypeptide" refers to, in addition to a polypeptide, an oligopeptide, peptide and a full protein.

Screening of p53 inactivation compounds:

[0094] Some of the compounds and compositions of the present invention may be used in a screening assay for identifying and isolating compounds that modulate the activity of p53, in particular compounds that modulate alopecia or acute renal failure or a disorder accompanied by an elevated level of p53 polypeptide. The compounds to be screened comprise *inter alia* substances such as small chemical molecules and antisense oligonucleotides.

[0095] The inhibitory activity of the compounds of the present invention on p53 polypeptide activity or binding of the compounds of the present invention to p53 may be used to determine the interaction of an additional compound with the p53 polypeptide, e.g., if the additional compound competes with the oligonucleotides of the present invention for p53 inhibition, or if the additional compound rescues said inhibition. The inhibition or activation can be tested by various means, such as, *inter alia*, assaying for the product of the activity of the p53 polypeptide or displacement of binding compound from the p53 polypeptide in radioactive or fluorescent competition assays.

[0096] The present invention is illustrated in detail below with reference to Examples, but is not to be construed as being limited thereto.

[0097] Citation of any document herein is not intended as an admission that such document is pertinent prior art, or considered material to the patentability of any claim of the present application. Any statement as to content or a date of any document is based on the information available to applicant at the time of filing and does not constitute an admission as to the correctness of such a statement.

20 EXAMPLES*General methods in Molecular biology*

[0098] Standard molecular biology techniques known in the art and not specifically described were generally followed as in Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, New York (1989), and as in Ausubel et al., Current Protocols in Molecular Biology, John Wiley and Sons, Baltimore, Maryland (1989) and as in Perbal, A Practical Guide to Molecular Cloning, John Wiley & Sons, New York (1988), and as in Watson et al., Recombinant DNA, Scientific American Books, New York and in Birren et al (eds) Genome Analysis: A Laboratory Manual Series, Vols. 1-4 Cold Spring Harbor Laboratory Press, New York (1998) and methodology as set forth in United States patents 4,666,828; 4,683,202; 4,801,531; 5,192,659 and 5,272,057. Polymerase chain reaction (PCR) was carried out generally as in PCR Protocols: A Guide To Methods And Applications, Academic Press, San Diego, CA (1990). *In situ* (In cell) PCR in combination with Flow Cytometry can be used for detection of cells containing specific DNA and mRNA sequences (Testoni et al., 1996, Blood 87:3822.) Methods of performing RT-PCR are also well known in the art.

35 EXAMPLE 1: Generation of sequences for active siRNA compounds

[0099] Using proprietary algorithms and the known sequence of gene p53 (SEQ ID NO:1), the sequences of many potential siRNAs were generated. Table A shows 23 siRNAs which have so far been selected, chemically synthesized and tested for activity (see Example 2). All these siRNAs are 19-mers.

40

45

50

55

5
10
15
20
25
30
35
40
45
50
55Table A

Number	Index	Sense strand	Antisense strand	Species	NM_000546 (human)	NM_011640 (mouse)	NM_030989 (rat)
1	Mo3	GUACAUAGGUAAAAGCUCC	GGAGCUAUUACACAUGUAC	mouse	3 mis	1232-1250	2 mis
2	Hu2'	GACUCAGGGUAAUCUAC	GUAGAUUACCACUGGAGUC	human*	1026-1044	3 mis	2 mis
3	QHMo n1	CAGACCUAUGGAAACUACU	AGUAGUUUCCAUAGGUCUG	hum, mon	310-328	3 mis	4 mis
4	QHMo n2	CUACCUCCGCCCAAAAAA	UUUUUAGGGGGAGGUAG	hum, mon	1378-1396	1 mis	1 mis
5	QH1	CCCAAGCAAUGGAUGAUUU	AAAUCAUCCCAUUGCJUJGG	human	361-379	No	No
6	QH2	CCCCGACGAAUUAUGAACAA	UUGUUCAAUAUCGUCCGGG	human	389-407	No	No
7	QM1	GAGUCACAGUGGGAUUAUC	UGAUAUCCGACUGUGACUC	mouse	No	552-570	2 mis
8	QM2	GGAUUGUGAGGAGUUUUU	AAAAAACUCCCUAACAUCC	mouse	No	680-698	4 mis
9	QM3	CAUCUUUGGUCCUUUCUCA	UGAGAAGGGACAAAGAUG	mouse	2 mis	808-826	2 mis
10	QM6	GGAAUAGGUUGAUAGUJGU	ACAACUAUCAACCUAUUCC	mouse	No	1870-1888	No
11	QM4	GGACAGCCAAGUCUGUUAU	AUAACAGACUJUJGGUJGUCC	mouse, rat	2 mis	877-895	527-545
12	QM5	GAAGAAAAUUUCCGCAAAA	UUUUGCGAAAAUUUUUUUC	mouse, rat	3 mis	1383-1401	1033-1051
13	A17	CUGGGACAGCCAAGUCUGU	ACAGACUUUGGUCCCCAG	hum, mus	598-616	874-892	2 mis
14	E2	UCAUCACACUGGAAGACUC	GAGCUUUCCAGUGUGAUGA	hum, mus, rat	1012-1030	1288-1306	938-956
15	E6	CACACUGGAAGACUCCAGU	ACUGGAGUCUUCCAGUGUG	hum, mus, rat	1016-1034	1292-1310	942-960
16	B1	GCGCCAUGGCCAUCAA	UUGUAGAUGGCCAUGGGCG	hum, mon, mus	724-742	1000-1018	652-668(17)
17	B2	CGCCAUGGCCAUCAAAG	CUUGUAGAUGGCCAUGGGCG	hum, mon, mus	725-743	1001-1019	652-669(18)
18	C1	AGUCACAGCACAUAGCGGA	UCCGUCAUGUGGUUGUGACU	hum, mon, mus	745-763	1021-1039	2 mis
19	F2	UCCGAGUGGAAGGAAUUU	AAAUUUCUUCACUCGGA	hum, mon, dog	835-853	1 mis	3 mis

(continued)

5
10
15
20
25
30
35
40
45
50
55

Number	Index	Sense strand	Antisense strand	Species	NM_000546 (human)	NM_011640 (mouse)	NM_030989 (rat)
20	F3	CCGAGUGGAAGGAAUUUUG	CAAAUUUCUUCCACUCGG	hum, mon, dog	836-854	1 mis	3 mis
21	G1	GACAGAAACACGUUUUCGAC	GUUCGAAAAGUGUUUCUGUC	hum, mon, dog	873-891	No	No
22	H2	GUGUGGGUGGCCUAUGA	UCAUAGGGCACCACACAC	hum, mon, dog	895-913	3 mis	3 mis
23	15	GAGAAUAUUUACCCUUCUA	UGAAAGGGUGAAAAUUCUC	hum, mon, dog	1225-1243	2 mis	1 mis

Note that in the above Table A, the sense strands of siRNAs 1-23 have SEQ ID NOS: 3-25 respectively, and the antisense strands of siRNAs 1-23 have SEQ ID NOS: 26-48 respectively. siRNA compound No 1 (SEQ ID NOS: 3 and 26) is known from the literature (Dirac and Bernards, Reversal of senescence in mouse fibroblasts through lentiviral suppression of p53, *J. Biol. Chem.* (2003) 278:11731) and siRNA No 2 (SEQ ID NOS:4 and 27) is also known from the literature (Brummelkamp et al. *Science* 2002, 296:550-553). However, the use of these compounds in the methods of treatment disclosed herein is previously undisclosed and thus novel.

[0100] Table B below shows 71 additional 19-mer siRNAs which have been generated by the proprietary algorithms.

5

10

15

20

25

30

35

40

45

50

55

5
10
15
20
25
30
35
40
45
50
55**Table B**

No.	Source	Sense	AntiSense	gi13097806 gbBC003596.1 (Homo sapiens)	gi2689466 gbU48957.1 U48957 (Macaca fascicularis)	gi53575emb X01237.1MMMP53R (Mouse mRNA)	gi499622 SdbjAB02 0761.1 (Canis familiaris)
1	Human	GUACCACCAUCCACUACAA	UGUAGUGGAUGGUUAC	[806-824]		[835-852]	
2	Human	GGAAACUACUUCUCCUGAAAA	UUUUUAGGAAGUAGUUUCC	[188-206]		[234-247]	
3	Human	AGACUCCAGUGGUAAUCUA	UAGAUUACCACUGGAGUCU	[894-912]		[922-933]	
4	Human	CCAUCGACUACAACUACAU	AUGUAGUJGUAGUGGAUGG	[812-830]		[840-858]	
5	Human	CCACCAUCCACUACAACUA	UAGUUGUAGUGGAUGGUGG	[809-827]		[837-852]	
6	Human	AAACACUUUUUCGACAUAGU	ACUAUGUCGAAAAUGUUU	[747-765]		-	
7	Human	CAUGAGCGCUGUCAGAU	UAUCUGAGCGAGCGCUAUG	[655-673]		[683-696]	
8	Human	CCAUGGCCAUCAACGCA	UGCUCUGUAGUGGCCAUGG	[596-614]		[624-640]	
9	Human	CCAAGUCUGUGACUUGCAC	GUGCAAGUCACAGACUUGG	[476-494]		-	
10	Human	AAACUUUUGCUGCCAAAAAA	UUUUUUGGCAGCAAAGUUU	[2476-2494]		-	
11	Human	CCCUCCUUCCCCUUUUUA	AAAAAAAGGGAGAAGGAGGG	[2421-2439]		-	
12	Human	GCAAGCACAUCUGCAUUUU	AAAUAUGCAGAUGUGCUUGC	[2389-2407]		-	
13	Human	GGGUCAACAUCUUUUACAU	AUGUAAAAGAUGUUGACCC	[2367-2385]		-	
14	Human	GAAGGGUCAACAUCUUUU	AAAAAAAGAUGUUGACCCUUC	[2364-2382]		-	
15	Human	CUGGAAGGGGUCAACAUUU	AAGAUGUUGACCCUUCAG	[2361-2379]		-	
16	Human	CCAGAGUGCGGGAUUACA	UGUAAUCCAGCACUCUGG	[2321-2339]		-	
17	Human	GAUGGGGUUCUCAGUGUU	AACACUGUGAGACCCCAUC	[2249-2267]		-	
18	Human	GCCAAACUUUUUGCAUGUUU	AAAACAUGCAAAGUUGGC	[2225-2243]		-	
19	Human	CCAUGGCCAGCCAAACUUUU	AAAAGUUGGUUGGCCAUGG	[2216-2234]		-	
20	Human	AGACCCAGGUCCAGAUGAA	UCAUCUGGUCCUGGGUCU	[288-306]		-	
21	Human, mouse	CCAUCAUCACACUGGAAGA	UCUUCCAGUGUGAUAGUG	[878-896]		[906-924]	

(continued)

5
10
15
20
25
30
35
40
45
50
55

No.	Source	Sense	AntiSense	gi13097806 gbBC003596.1 (Homo sapiens)	gi2689466 gbU48957.1 (Macaca fascicularis)	gi53575emb X01237 .1MMP53R (Mouse mRNA)	gi499622 SdbjAB02 0761.1 (Canis familiaris)
22	Human, mouse	CAUCACACUGGAAGACUCC	GGAGUCUUCCAGUGUAUG	[882-900]		[910-928]	
23	Human, mouse	CAUCAUCACACUGGAAGAC	GUCUUCCAGUGUAUGUAUG	[879-897]		[907-925]	
24	Human, mouse	ACCAUCAUCACACUGGAAG	CUUCCAGUGUGAUGAUGGU	[877-895]		[905-923]	
25	Human, mouse	AUCAUCACACUGGAAGACU	AGUCUUCCAGUGUGAUGAU	[880-898]		[908-926]	
26	Human, mouse	CACUGGAAGACUCCAGUG	CCACUGGAGAGUCUUCCAGUG	[887-905]		[915-933]	
27	Human, cynomoglus, mouse	ACACUGGAAGACUCCAGUG	CACUGGAGAGUCUUCCAGUGU	[886-904]	[766-784]	[914-932]	
28	Human, cynomoglus, mouse	UCACACUGGAAGACUCCAG	CUGGAGUCUUCCAGUGUGA	[884-902]	[764-782]	[912-930]	
29	Human, cynomoglus, mouse	AUCACACUGGAAGACUCCA	UGGAGUCUUCCAGUGUGAU	[883-901]	[763-781]	[911-929]	
30	Human, cynomoglus, mouse	CACAGCACAUGACGGAGGU	ACCUCCGUCAUGUGCUGUG	[617-635]	[497-515]	[645-663]	
31	Human, cynomoglus, mouse	CACUGGAAGACUCCAGUGG	CCACUGGAGAGUCUUCCAGUG	[887-905]	[767-785]	[915-933]	

5

10

15

20

25

30

35

40

45

50

55

(continued)

No.	Source	Sense			gi13097806 gbBC003596.1 (Homo sapiens)	gi2689466 gbU48957.1 (Macaca fascicularis)	gi53575emb X01237 .1MMP53R (Mouse mRNA)	gi499622 SdbjAB02 0761.1 (Canis familiaris)
32	Human, cynomolgus, mouse	UCACAGGCCACAUGACGGAGG	AntiSense	CCUCCGUCAUGUGCUGUGA	[616-634]	[496-514]	[644-662]	
33	Human, cynomolgus, mouse	GUACACAGGCACACAUGACGGAG		CUCCGUCAUGUGCUGUGAC	[615-633]	[495-513]	[643-661]	
34	Human, cynomolgus, dog	CCAUCCACUACAACUACAU		AUGUAGUUAGUGGAUGGG	[812-830]	[692-710]		[702-720]
35	Human, cynomolgus, dog	CCACCAUCCACUACAACUA		UAGUUGUAGUGGAUGGGGG	[809-827]	[689-707]		[699-717]
36	Human, cynomolgus, dog	GAUAUUUACCCUUACAGA		UCUGAAGGGUGAAAUUUC	[1096-1114]	[976-994]		
37	Human, cynomolgus, dog	CGAGUGGAAGGAAAUUUGC		GCAAAUUUCCUUCACUCG	[706-724]	[586-604]		[986-1004]
38	Human, cynomolgus, dog	GAGAAAUUUUCACCUUCA		UGAAGGGUGAAAUUUCUC	[1094-1112]	[974-992]		[596-614]
39	Human, cynomolgus, dog	CUACAUGUGUAACAGUUCC		GAACUGUUACACAGUAG	[825-843]	[705-723]		[984-1002]
40	Human, cynomolgus, dog	AACUACAUGUGUAACAGUU		AACUGUUACACAGUAGUU	[823-841]	[703-721]		[713-731]

5

10

15

20

25

30

35

40

45

50

55

(continued)

No.	Source	Sense	AntiSense	gi13097806 gbBC003596.1 (Homo sapiens)	gi2689466 gbU48957.1 (Macaca fascicularis)	gi53575emb X01237 .1MMP53R (Mouse mRNA)	gi499622 SdbjAB02 0761.1 (Canis familiaris)
41	Human, cynomoglii, dog	CAACUACAUAGGUACAGU	ACUGUUACACAUGUAGUUG	[822-840]	[702-720]		[712-730]
42	Human, cynomoglii, dog	CACUACAAACUACAUUGUA	UACACAUAGUAGUAGUAGUG	[817-835]	[697-715]		[707-725]
43	Human, cynomoglii, dog	CCACUACAAACUACAUUGUGU	ACACAUAGUAGUAGUGGG	[816-834]	[696-714]		[706-724]
44	Human, cynomoglii, dog	GACAGAAACACUUUUCGAC	GUCGAAAAGUGUUUCUGUC	[742-760]	[622-640]		[632-650]
45	Human, cynomoglii, dog	GGGAAUAAUUCACCCUUC	GAAGGGUGAAAUUUCUCC	[1093-1111]	[973-991]		[983-1001]
46	Human, cynomoglii, dog	GUGAACAGUUCUGCAG	CAUGCAGGAACUGUACAC	[831-849]	[711-729]		[721-739]
47	Human, cynomoglii, dog	ACAAACUACAUUGUAAACAG	CUGUUACACAUAGUAGUUGU	[821-8391	[701-719]		[711-729]
48	Human, cynomoglii, dog	ACUACAAACUACAUUGUAA	UUACACAUAGUAGUAGU	[818-836]	[698-716]		[708-726]
49	Human, cynomoglii, dog	ACCAUCCACUACAAACUACA	UGUAGUUGUAGUGGAUGGU	[811-829]	[691-709]		[701-719]

5

10

15

20

25

30

35

40

45

50

55

(continued)

No.	Source	Sense	AntiSense	gi13097806 gbBC003596.1 (Homo sapiens)	gi2689466 gbU48957.1 (Macaca fascicularis)	gi53575emb X01237 .1MMP53R (Mouse mRNA)	gi499622 SdbjAB02 0761.1 (Canis familiaris)
50	Human, cynomoglii, dog	ACCACCAUCCACUACAACU	AGUUAGUGGAUGGGGUU	[808-826]	[688-706]		[698-716]
51	Human, cynomoglii, dog	UACCACCAUCCACUACAAAC	GUUGUAGUGGAUGGGGUU	[807-825]	[687-705]		[697-715]
52	Human, cynomoglii, dog	ACAGAAAACACUUUUCGACA	UGUCGAAAAGUGUUUCUGU	[743-761]	[623-641]		[633-651]
53	Human, cynomoglii, dog	GAGGGAAAGGAAAUUUGCG	CGCAAAUUUCCUUCACUC	[707-725]	[587-605]		[597-615]
54	Human, cynomoglii, dog	AUAUUUACCCUUUCAGAUC	GAUCUGAAGGGUGAAAUAU	[1098-1116]	[978-996]		[988-1006]
55	Human, cynomoglii, dog	AAUAAUUCACCUUUCAGAU	AUCUGAAGGGUGAAAUUU	[1097-1115]	[977-995]		[987-1005]
56	Human, cynomoglii, dog	AGAAUAAUUCACCCUUCAG	CUGAAGGGUGAAAUUUUCU	[1095-1113]	[975-993]		[985-1003]
57	Human, cynomoglii, dog	UGGAGAAUAAUUCACCUU	AAGGGUGAAAUUUUCUCCA	[1092-1110]	[972-990]		[982-1000]
58	Human, cynomoglii, dog	ACAUUGUGUAACAGUUCCUG	CAGGAACUGUUACACAUGU	[827-845]	[707-725]		[717-735]

5

10

15

20

25

30

35

40

45

50

55

(continued)

No.	Source	Sense	AntiSense	gi13097806 gbBC003596.1 (Homo sapiens)	gi2689466 gbU48957.1 (Macaca fascicularis)	gi53575emb X01237 .1MMP53R (Mouse mRNA)	gi499622 SdbjAB02 0761.1 (Canis familiaris)
59	Human, cynomoglii, dog	UACAAUACAUGUGUAACA	UGUUACACAUAGUUGUA	[820-838]	[700-718]		[710-728]
60	Human, cynomoglii, dog	CUACAAUACAUGUGAAC	GUUACACAUAGUUGUAG	[819-837]	[699-717]		[709-727]
61	Human, cynomoglii, dog	UCCACUACAAUACAUGUG	CACAUAGUUGUAGUGGA	[815-833]	[695-713]		[705-723]
62	Human, cynomoglii, dog	AUCCACUACAAUACAUGU	ACAUGUAGUUGUAGUGGAU	[814-832]	[694-712]		[704-722]
63	Human, cynomoglii, dog	CAUCCACUACAAUCUACAUG	CAUGUUGUAGUGGAUG	[813-831]	[693-711]		[703-721]
64	Human, cynomoglii, dog	CACCAUCCACUACAUCUAC	GUAGUUUGUAGUGGUG	[810-828]	[690-708]		[700-718]
65	Human, cynomoglii, dog	UGUGUAACAGUUCUGCAU	AUGCAGGAACUGUUACACACA	[830-848]	[710-728]		[720-738]
66	Human, cynomoglii, dog	CAUGUGUAACAGUUCUGC	GCAGGAACUGUUACACAU	[828-846]	[708-726]		[718-736]
67	Human, cynomoglii, dog	UACAUUGUAAACAGUUCU	AGGAACUGUUACACAU	[826-844]	[706-724]		[716-734]

5
10
15
20
25
30
35
40
45
50
55

(continued)

No.	Source	Sense				
68	Human, cynomoglius, dog	ACUACAUGUGUAACAGUUC	GAACUGUUACACAUGUAGU	[824-842]	[704-722]	[714-732]
69	Human, cynomoglius, dog	AUCCGAGUGGAAGGAAAUU	AAUUUUCCUCCACUCUGGAU	[703-721]	[583-601]	[593-611]
70	Human, cynomoglius, dog	UCACUCCAGGCCACCUGAAG	CUUCAGGUCCUGGAGUGA	[1212-12301]	[1092-11101]	[1102-11201]
71	Human, cynomoglius, dog	CUCACUCCAGGCCACCUGAA	UUCAGGUCCUGGAGUGAG	[1211-1229]	[1091-1109]	[1101-1119]

Note that in the above Table B, the sense strands of siRNAs 1-71 have SEQ ID NOS: 49-119 respectively, and the antisense strands of siRNAs 1-71 have SEQ ID NOS: 120- 190 respectively.

[0101] Table C below shows 63 additional 21-mer siRNAs which have been generated by the proprietary algorithms.

5

10

15

20

25

30

35

40

45

50

55

5
10
15
20
25
30
35
40
45
50
55Table C

No.	Source	Sense SiRNA	AntiSense SiRNA	Reference	Reference	Reference
1	Human	GGAAAGAGAAUCUCCGGCAAGAA	UUCUUUGGGAGAGAUUCUUCC	[975-995]	-	-
2	Human	GUACCACCAUCCACUACAU	AGUUUAGUGGAUGGGGUAC	[806-826]	[686-706]	[835-852]
3	Human	GGACGAUAAUUGAACAAUAGGUU	AACCAUUGUCAAUAUCCGUCC	[261-281]	-	-
4	Human	CCAGGCACCCUGGAAGGUCCCCAA	UUUUGGACUUUCAGGUCCUGG	[1217-1237]	[1097-1115]	-
5	Human	GAGAAUAAUUCACCCUUUCAGA	UCUGAAGGGUGAAAUUUUCUC	[1094-1114]	[974-994]	[1122-1137]
6	Human	AGAAACCACUGGAUGGGAAAU	AUUCUCCAUCCAGGUUUUCU	[1079-1099]	[959-979]	-
7	Human	CUACUGGGACGGAACAGCUUU	AAAGCUGUCCGUCCAGUAG	[910-930]	[790-810]	-
8	Human	AGACUCCAGUGGUAAAUCUACU	AGUAGAUUACCACUGGAGUCU	[894-914]	[774-794]	[922-933]
9	Human	CUGGAAGACUCCAGUGGUAAU	AUUACCACUGGAGUCUUCAG	[889-909]	[769-789]	[917-933]
10	Human	GAAACUACUUCCUGAAAACAA	UUGUUUUUAGGAAGUAGUUUC	[189-209]	[69-87]	[235-247]
11	Human	GGAAACUACUUCCUGAAAACA	UGUUUUUAGGAAGUAGUUUC	[188-208]	[68-87]	[234-247]
12	Human	AAACACUUUUUGGACAUAGUGU	ACACUAUGUGGAAAAGUUUU	[747-767]	[627-647]	[637-657]
13	Human	GGAGUAUUUUUGGAUGACAGAA	UUUCUGUCAUCCAAAUCUCC	[729-749]	[609-629]	-
14	Human	UCAGACCUCUAGGAAAUCUUCU	AAGUAGUUIUCCAUAGGUCUGA	[178-198]	[58-78]	[231-244]
15	Human	CCAUGGCCAUCAAGCAGU	ACUGCUUGUAGUGGCCAUGG	[596-616]	[476-496]	[624-640]
16	Human	CCAAGUCUGUGACUUCGACGU	ACGUGCAAGUCACAGACUUUG	[476-496]	[356-376]	-
17	Human	GGACAGCCAAGUCUGUGACUU	AAGUCACAGACUUGGCUGUCC	[470-490]	[352-370]	[498-513]
18	Human	CCCUCCUUUCUCCUUUUUAUA	UAUAAAAAGGGAGAAGGAGGG	[2421-2441]	-	[1721-1731]
19	Human, cynomolgus, dog	CCAUCCACUACAAACUACAU	ACAUAGUUGUAGUGGAUGG	[812-832]	[692-712]	[840-860]
20	Human, cynomolgus, dog	CCACCAUCCACUACAAACUACA	UGUAGUUGUAGUGGAUGGUGG	[809-829]	[689-709]	[837-857]

5

10

15

20

25

30

35

40

45

50

55

(continued)

No.	Source	Sense SiRNA	AntiSense SiRNA	gi2689466 gbU48957.1 U48957 (Macaca fascicularis)	gi53575emb X01237.1M MP53R (Mouse mRNA)	gi4996229dbj AB020761.1 (Canis familiaris)
21	Human, cynomolgus, dog	GAGAAUUUUACCCUUCAGA	UCUGAAGGGUGAAAAUAUUCUC	[1094-1114]	[974-994]	[984-1004]
22	Human, cynomolgus, dog	GGAGAAUUUUACCCUUCAG	CUGAAGGGUGAAAAUAUUCUC	[1093-1113]	[973-993]	[983-1003]
23	Human, cynomolgus, dog	CUACAUUGUAAACAGUUCUG	CAGGAACUGUUACACAUAG	[825-845]	[705-725]	[715-735]
24	Human, cynomolgus, dog	ACAAACUACAUGUGUAACAGUU	AACUGUUACACAUGUAGUU	[821-841]	[701-721]	[711-731]
25	Human, cynomolgus, dog	CCACUACAACUACAUGUJAA	UUACACAUUGUAGUUGUG	[816-836]	[696-716]	[706-726]
26	Human, cynomolgus, dog	CACCAUCCACUACAACUACAU	AUGUAGUUGUAGUGGAUGGUG	[810-830]	[690-710]	[700-720]
27	Human, cynomolgus, dog	GAAUAUUUACCCUUCAGAUC	GAUCUGAAGGGUGAAAAUUC	[1096-1116]	[976-996]	[986-1006]
28	Human, cynomolgus, dog	AGAAUAUUUACCCUUCAGAU	AUCUGAAGGGUGAAAAUUCU	[1095-1115]	[975-995]	[985-1005]
29	Human, cynomolgus, dog	UACCAACCAUCCACUACAU	UAGUUGUAGUGGAUGGUGUA	[807-8271]	[687-707]	[697-717]

5

10

15

20

25

30

35

40

45

50

55

(continued)

No.	Source	Sense SiRNA	AntiSense SiRNA	gi2689466 gbU48957.1 U48957 (Macaca fascicularis)	gi13097806 gbBC003596.1 (Homo sapiens)	gi53575emb X01237.1M MP53R (Mouse mRNA)	gi4996229dbj AB020761.1 (Canis familiaris)
30	Human, cynomolgus, dog	GAUGGAGAAUAAAUCACCUU	AAGGGUGAAAUUUUCACCUU	[1090-1110]	[970-990]		[980-1000]
31	Human, cynomolgus, dog	CCGAGUGGAAGGAAAUUUGCG	CGCAAAUUUCCUUCACUCGG	[705-725]	[585-605]		[595-615]
32	Human, cynomolgus, dog	AACUACAAUGUGUAAACAGUUC	GGAACUGUUACACAGUAGUU	[823-843]	[703-723]		[713-733]
33	Human, cynomolgus, dog	CAACUACAAUGUGUAAACGUUC	GAACUGUUACACAGUAGUU	[822-842]	[702-722]		[712-732]
34	Human, cynomolgus, dog	ACUACAAUCAUGUGUAACA	UGUUACACAAUGUAGUUGUAGU	[818-838]	[698-718]		[708-728]
35	Human, cynomolgus, dog	CACUACAAACUACAUUGUAAAC	GUUACACAAUGUAGUUGUAGUG	[817-837]	[697-717]		[707-727]
36	Human, cynomolgus, dog	UCCACUACAAACUACAUUGUA	UACACAAUGUAGUUGUGGGA	[815-835]	[695-715]		[705-725]
37	Human, cynomolgus, dog	CAUCCACUACAAACUACAUUG	CACAUAGUAGUUGUGGAUG	[813-833]	[693-713]		[703-723]
38	Human, cynomolgus, dog	ACCAUCCACUACAAUCUACAU	CAUGUAGUUGUAGUGGAUGGU	[811-831]	[691-711]		[701-721]

5

10

15

20

25

30

35

40

45

50

55

(continued)

No.	Source	Sense SiRNA	AntiSense SiRNA	gi2689466 gbU48957.1 U48957 (Macaca fascicularis)	gi13097806 gbBC003596.1 (Homo sapiens)	gi53575emb X01237.1M MP53R (Mouse mRNA)	gi4996229dbj AB020761.1 (Canis familiaris)
39	Human, cynomolgus, dog	UGGAGAAUUCACCCUUC	UGAAGGGUGAAAUUCUCCA	[1092-1112]	[972-992]		[982-1002]
40	Human, cynomolgus, dog	AUGUGAACAGUUCCUGCAUG	CAUGCAGGAACUGUUACACAU	[829-849]	[709-729]		[719-739]
41	Human, cynomolgus, dog	CAUGUGAACAGUUCCUGCAU	AUGCAGGAACUGUUACACAU	[828-848]	[708-728]		[718-738]
42	Human, cynomolgus, dog	UACAAACUACAUGGUAAACAGU	ACUGUUACACAUAGGUUGUA	[820-840]	[700-720]		[710-730]
43	Human, cynomolgus, dog	CUACACUACAUGGUAAACAG	CUGUUACACAUAGGUUGUAG	[819-839]	[699-719]		[709-729]
44	Human, cynomolgus, dog	AUCCACUACAACUACAU	ACACAUAGUAGUAGUGGAGU	[814-834]	[694-714]		[704-724]
45	Human, cynomolgus, dog	ACCCACCAUCCACUACAACUAC	GUAGUUAGUGGAUGGGGU	[808-828]	[688-708]		[698-718]
46	Human, cynomolgus, dog	AAUAAUUCACCCUUCAGAUCC	GAUCUGAAGGGUGAAAUAU	[1097-1117]	[977-997]		[987-1007]
47	Human, cynomolgus, dog	ACUACAUUGUAAACAGUUCCU	AGGAACUGUUACACAUAGU	[824-844]	[704-724]		[714-734]

(continued)

No.	Source	Sense SiRNA	AntiSense SiRNA	gi2689466 gbU48957.1 U48957 (Macaca fascicularis)	gi53575emb X01237.1M MP53R (Mouse mRNA)	gi4996229dbj AB020761.1 (Canis familiaris)
48	Human, cynomolgus, dog	AUGGAGAAUUAUUCACCCUUC	GAAGGGUGAAAAUUAUCUCCAU	[1091-1111]	[971-991]	[981-1001]
49	Human, cynomolgus, dog	UGUGUAACAGUUUCCUGCAUGG	CCAUGCAGGAACUGUUACACAA	[830-850]	[710-730]	[720-740]
50	Human, cynomolgus, dog	UCCGAGUGGAAGGAAUUUUGC	GCAAAUUUCCUUCACUCUGGA	[704-724]	[584-604]	[594-614]
51	Human, cynomolgus, dog	AUCCGGAGUGGAAGGAAUUUUG	CAAAAUUCCUUCACUCGGAU	[703-723]	[583-603]	[593-613]
52	Human, cynomolgus, mouse	UCACACUGGAAGACUCCAGU	CACUGGAGCUUCCAGUGUGA	[884-904]	[764-784]	[912-932]
53	Human, cynomolgus, mouse	AUCACACUGGAAGACUCCAGU	ACUGGAGCUUCCAGUGUAU	[883-903]	[763-783]	[911-931]
54	Human, cynomolgus, mouse	CACACUGGAAGACUCCAGUGG	CCACUGGAGCUUCCAGUGUG	[885-905]	[765-785]	[913-933]
55	Human, mouse	UCAUCAACACUGGAAGACUCCA	UGGAGUCUUCAGUGUGAUGA	[881-901]		[909-929]
56	Human, mouse	CCAUCAUCACACUGGAAGACU	AGUCUUCCAGUGUGAUGG	[878-898]		[906-926]
57	Human, mouse	CAUCACACUGGAAGACUCCAG	CUGGAGCUUCCAGUGUGAUG	[882-902]		[910-930]

(continued)

No.	Source	Sense SiRNA	AntiSense SiRNA	gi2689466 gbU48957.1 U48957 (Macaca fascicularis)	gi13097806 gbBC003596.1 (Homo sapiens)	gi53575emb X01237.1M MP53R (Mouse mRNA)	gi4996229dbj AB020761.1 (Canis familiaris)
58	Human, mouse	CAUCAUCACACUGGAAGACUC	GAGUCUUCCAGUGUGAUGAUG	[879-899]			[907-927]
59	Human, mouse	ACCAUCAUCACACUGGAAGAC	GUCUUCCAGUGUGAUGAUGGU	[877-897]			[905-925]
60	Human, mouse	UCACACUGGAAGACUCCAGUG	CACUGGAGUCUUCCAGUGUGA	[884-904]			[912-932]
61	Human, mouse	AUCACACUGGAAGACUCCAGU	ACUGGAGUCUUCCAGUGUGAU	[883-903]			[911-931]
62	Human, mouse	AUCAUCACACUGGAAGACUCC	GGAGUCUUCCAGUGUGAUGAU	[880-900]			[908-928]
63	Human, mouse	CACACUGGAAGACUCCAGUGG	CCACUGGAGUCUUCCAGUGUG	[885-905]			[913-933]

Note that in the above Table C, the sense strands of siRNAs 1-63 have SEQ ID NOS: 191-253 respectively, and the antisense strands of siRNAs 1-63 have SEQ ID NOS: 254-316 respectively.

EXAMPLE 2: Testing the siRNA compounds for anti-p53 activity

Protocols

5 I. Preparation of the siRNAs (double-stranded oligonucleotides)

[0102] Lyophilized oligonucleotides were dissolved in RNase free distilled water to produce a final concentration of 100uM. The diluted oligonucleotides were kept at room temperature for 15 min and immediately frozen in liquid nitrogen. The oligonucleotides were stored at -80°C and diluted before use with PBS.

10 II. Transfection of siRNA in human cells with Lipofectamine2000 reagent:

[0103] 2x10⁵ p53-wt HCT116 or SW480 cells were seeded per well in 6 wells plate. 24h subsequently, cells were transfected with p53 oligonucleotides using lipofectamine2000 reagent (obtained from Invitrogen).

15 The following procedure was performed:

1. Before transfection, the cell medium was replaced by 1500ul fresh medium without antibiotics.
2. In a sterile, plastic tube, Lipofectamine2000 reagent (the amount is calculated according to 5ul per well) was added to 250ul serum-free medium, and incubated for 5 min at room temperature.
- 20 3. In another tube the human anti- p53 oligonucleotides (varying amounts to fit the desired final concentration per well) were added to 250ul serum-free medium.
4. Lipofectamine2000 complex was combined with the p53 oligonucleotide solution and incubated for 20 min at room temperature.
5. The resulting mixture was added dropwise to the cells, and the cells were incubated at 37°C.
- 25 6. SW480 cells: 48 hr after transfection the cells were harvested and proteins were extracted using RIPA buffer.
7. HCT116 cells:

30 ■ 40h after transfection, 5Fu (Sigma) was added to cells to produce a final concentration of 25ug/m1. 48h after cells transfection (8h after 5Fu treatment), the cells were harvested and proteins were extracted using RIPA buffer.

8. p53 expression was determined by Western Blot analysis using monoclonal antibody (Do-1 clone, Santa Cruz). For normalization, blots were examined for Tubulin expression.

35 III Co-Transfection of mouse p53 gene and mouse p53 oligonucleotides into PC3 cells using Lipofectamine2000 reagent:

[0104] 2x10⁵ p53-null PC3 cells were seeded per well in 6 wells plate. 24h subsequently, cells were Co-transfected with mouse p53 gene and GFP gene and mouse p53 oligonucleotides using lipofectamine2000 reagent (Invitrogen).

40 The following procedure was performed:

1. Before transfection cell medium was replaced by 1500ul fresh medium without antibiotics.
2. In sterile, plastic tube, Lipofectamine2000 reagent (5ul per well) was added to 250ul serum-free medium, and incubated for 5 min at room temperature.
- 45 3. In another tube 4ug DNA (p53gene:GFPgene, 10:1) and human p53 oligonucleotides were added to 250ul serum free medium.
4. Lipofectamine2000 complex was combined with p53 oligonucleotides solution and incubated for 20 min at room temperature.
5. The mixture solution was added dropwise to the cells, and cells were incubated at 37°C.
- 50 6. 48h after transfection, cells were harvested and proteins were extracted using RIPA buffer.
7. p53 expression was determined by Western Blot analysis using monoclonal antibody (Clone240, Chemicon). For normalization, blots were examined for GFP expression.

55 Results:**A. Human p53 oligonucleotides:**

[0105]

Table D:

Number	oligo	species	source	Results of Test	
				SW480	HCT116
2	Hu2'	human	literature	(-)	(+)
3	QHMon1	human, monkey	Proprietary	(++)	(+++)
4	QHMon2	human, monkey	Proprietary	(-)	Not tested
5	QH1	human	Proprietary	(+++)	(+++)
6	QH2	human	Proprietary	(-)	Not tested
13	A17	human, mouse	Proprietary	(-)	Not tested
14	E2	human, mouse, rat	Proprietary	(+)	Not tested
15	E6	human, mouse, rat	Proprietary	(-)	Not tested
16	B1	human, mouse, rat	Proprietary	(-)	Not tested
17	B2	human, mouse, rat	Proprietary	(-)	Not tested
18	C1	human, monkey, mouse	Proprietary	(-)	Not tested
19	F2	human, monkey, dog	Proprietary	(-)	Not tested
20	F3	human, monkey, dog	Proprietary	(+++)	(+++)
21	G1	human, monkey, dog	Proprietary	(+++)	Not tested
22	H2	human, monkey, dog	Proprietary	(+)	Not tested
23	I5	human, monkey, dog	Proprietary	(+++)	Not tested
Note: The numbers in Table D correspond to the numbers used in Table A, where the sense strands of siRNAs 1-23 have SEQ ID NOS: 3-25 respectively, and the antisense strands of siRNAs 1-23 have SEQ ID NOS: 26-48 respectively.					

[0106] As shown in Table D, four human oligonucleotides were tested in two systems SW480 and HCT116 , according to Protocols II above . Representative results (Western Blot) on which the *Results of Test* was based are shown in Figure 3 .

B. Mouse p53 oligonucleotides:

[0107]

Table E:

	oligo	species	source	Results of Test	
				PC3 null cells/exogenous mouse p53	
1	Mo3	mouse	literature	(+++)	
7	QM1	mouse	Proprietary	(-)	
8	QM2	mouse	Proprietary	(-)	
9	QM3	mouse	Proprietary	(-)	
10	QM6	mouse	Proprietary	(-)	
11	QM4	mouse, rat	Proprietary	(+++)	
12	QM5	mouse, rat	Proprietary	(+++)	
13	A17	human, mouse	Proprietary	(-)	
14	E2	human, mouse, rat	Proprietary	(++)	

(continued)

5	oligo	species	source	Results of Test
				PC3 null cells/exogenous mouse p53
15	E6	human, mouse, rat	Proprietary	(-)
16	B1	human, monkey, mouse	Proprietary	(-)
17	B2	human, monkey, mouse	Proprietary	(++)
18	C1	human, monkey, mouse	Proprietary	(++)
21	G1	human, monkey, dog	Proprietary	(++)
20	F3	human, monkey, dog	Proprietary	(+++)
23	I5	human, monkey, dog	Proprietary	(-)
3	QHMon1	human, monkey	Proprietary	(++)

Note: The numbers in Table E (as for Table D) correspond to the numbers used in Table A, where the sense strands of siRNAs 1-23 have SEQ ID NOS: 3-25 respectively, and the antisense strands of siRNAs 1-23 have SEQ ID NOS: 26- 48 respectively. Representatives of the Western Blot results on which the *Results of Test* was based are shown in Figure 4.

EXAMPLE 3: Model systems of hair loss.

25 [0108] Testing the active siRNA may be done in the following systems:

- Mouse model of hair loss
- Ex-vivo cultured human hair follicles
- Human hair follicle graft in nude mice

30 Note: Systems for testing the active siRNA are described in Botcharev et al, 2000, *p53 is essential for Chemotherapy-induced Hair Loss*, *Cancer Research*, 60, 5002-5006).**EXAMPLE 4: Model systems of acute renal failure (ARF).**

35 [0109] Testing the active siRNA for treating ARF may be done using sepsis-induced ARF or ischemia-reperfusion-induced ARF.

40 1. Sepsis induced ARF

[0110] Two predictive animal models of sepsis-induced ARF are described by Miyaji T, Hu X, Yuen PS, Muramatsu Y, Iyer S, Hewitt SM, Star RA, 2003, Ethyl pyruvate decreases sepsis-induced acute renal failure and multiple organ damage in aged mice, *Kidney Int. Nov*;64(5):1620-31. These two models are lipopolysaccharide administration and cecal ligation puncture in mice, preferably in aged mice.

45 2. Ischemia-reperfusion-induced ARF

[0111] This predictive animal model is described by Kelly KJ, Plotkin Z, Vulgamott SL, Dagher PC, 2003 January, *P53 mediates the apoptotic response to GTP depletion after renal ischemia-reperfusion: protective role of a p53 inhibitor*, *J Am Soc Nephrol.*; 14(1):128-38.

[0112] Ischemia-reperfusion injury was induced in rats following 45 minutes bilateral kidney arterial clamp and subsequent release of the clamp to allow 24 hours of reperfusion. 250 µg of p53 siRNA (QM5 sequence, Table A) were injected into the jugular vein 2 hrs prior to and 30 minutes following the clamp. Additional 250µg of siRNA were given via the tail vein at 4 and 8 hrs after the clamp. siRNA against GFP served as a negative control. The siRNA used in the experiments described herein had a phosphate group at the 3' terminus of both the sense and antisense strand. The 3'-non-phosphorylated siRNA has been found to have similar biologically activity in an animal model as the corresponding 3'-phosphorylated siRNA. ARF progression was monitored by measurement of serum creatinine levels before and 24 hrs post surgery. At the end of the experiment, the rats were perfused via an indwelling femoral line with warm PBS

followed by 4% paraformaldehyde. The left kidneys were removed and stored in 4% paraformaldehyde for subsequent histological analysis. Acute renal failure is frequently defined as an acute increase of the serum creatinine level from baseline. An increase of at least 0.5 mg per dL or 44.2 μ mol per L of serum creatinine is considered as an indication for acute renal failure. Serum creatinine was measured at time zero before the surgery and at 24 hours post ARF surgery.

5 [0113] To study the distribution of p53 siRNA in the rat kidney, Cy3-labeled 19-mer blunt-ended siRNA molecules (2 mg/kg) having alternating O-methyl modification in the sugar residues were administered iv for 3-5 min, after which *in vivo* imaging was conducted using two-photon confocal microscopy. The confocal microscopy analysis revealed that the majority of siRNA in the kidneys is concentrated in the endosomal compartment of proximal tubular cells. Both endosomal and cytoplasmic siRNA fluorescence were relatively stable during the first 2 hrs post delivery and disappeared at 24 hrs.

10 15 [0114] As evident from Figure 5, there was a ten-fold increase in the level of serum creatinine following the 45-min of kidney bilateral arterial clamp treatment (PBS treatment). Four injections of p53 siRNA (QM5 sequence, Table A) (2 hrs prior to the clamp and 30min, 4h and 8h after the clamp) significantly reduced the creatinine level in serum by 50% ($P < 0.001$). These results suggest that p53 siRNA can protect renal tissue from the effects of ischemia-reperfusion injury and thus reduces the severity of ARF.

20 25 [0115] The effect of p53 siRNA treatment on renal ischemia-reperfusion injury was further determined by analysing the extent of tubular necrosis in the renal tissue. Tubular necrosis may be scored as: no damage (damage scoring 0), unicellular, patchy isolated necrosis (damage scoring 1), tubular necrosis in less than 25% of the tissue (damage scoring 2), tubular necrosis in between 25 and 50% of the tissue (damage scoring 3) and tubular necrosis in more than 50% of the tissue (damage scoring 4). Figure 6 demonstrates the tubular kidney damage expressed as damage scoring (Y-axis) in animals that did not undergo ischemia-reperfusion injury (group 1) or in ischemia-reperfusion injury animals following treatment with either PBS (group 2), two injections of p53 siRNA (group 3), three injections of p53 siRNA (group 4) or four injections of p53 siRNA (group 5). As revealed by Figure 6, four injections of p53 siRNA led to significant decrease in the tubular kidney damage as compared to the PBS control group. Figure 7 demonstrates that four injections of p53 siRNA treatment down-regulated the expression of the pro-apoptotic gene Puma in the cortical compartment of the kidney in animal subjected to ischemia-reperfusion injury. This indicates that p53 siRNA treatment is capable of inhibiting the apoptotic processes in the kidney following ischemia-reperfusion injury.

30 Claims

1. A double-stranded siRNA compound having the structure:

35 5' ugaaggugaaaaauuucuc - Z 3' (antisense strand SEQ ID NO:48)
3' Z'-acuuucccacuuuaagag (sense strand SEQ ID NO:25);

wherein each a, c, u and g is a ribonucleotide and each consecutive ribonucleotide is joined to the next ribonucleotide by a covalent bond ; and

40 wherein each of Z and Z' may be present or absent, but if present is dTdT and is covalently attached at the 3' terminus of the strand in which it is present; and

45 wherein alternating ribonucleotides in both the antisense strand and the sense strand are modified in their sugar residue such that a 2'-O-Methyl group is present and 2'-O-Methyl sugar modified ribonucleotides are present at the 5' terminus and the 3' terminus of the antisense strand and unmodified ribonucleotides are present at the 5' terminus and the 3' terminus of the sense strand.

2. The compound of claim 1, wherein the covalent bond is a phosphodiester bond.

3. The compound of claim 1 or 2, wherein Z and Z' are both absent.

4. The compound of claim 1, 2 or 3, wherein the ribonucleotide at the 3' terminus and the ribonucleotide at the 5' terminus in the antisense strand and the sense strand are non-phosphorylated.

5. The compound of claim 1, 2 or 3, wherein the ribonucleotide at the 3' terminus in the antisense strand and the ribonucleotide at the 3' terminus in the sense strand are phosphorylated.

55 6. A pharmaceutical composition comprising the compound of any one of claims 1 to 5 in an amount effective to down-regulate expression of a human p53 gene; and a carrier.

7. The compound of any one of claims 1 to 5, for use in therapy.

8. The compound according to anyone of claims 1-5, for use in treating or preventing acute renal failure.

5 9. The compound for use as in claim 8, wherein the acute renal failure follows major cardiac surgery or vascular surgery.

10 10. The compound for use as in claim 9, wherein the acute renal failure follows major cardiac surgery.

11. The compound according to anyone of claims 1-5, for use in treating alopecia.

12. The compound according to anyone of claims 1-5, for use in improving graft tissue survival following transplantation.

15 13. The compound according to anyone of claims 1-5, for use in preventing ischemic acute renal failure in a kidney transplant patient.

14. The compound for use as in any one of claims 8 to 13, wherein said compound is to be administered by systemic administration.

20 15. The compound according to anyone of claims 1-5, for use in treating brain injury and spinal cord injury.

16. The compound for use as in claim 15, wherein the brain injury is a seizure.

17. The compound according to anyone of claims 1-5, for use in treating cisplatin-induced deafness.

25 18. The compound for use as in claim 11 or 17, wherein said compound is to be administered by topical administration.

19. The compound for use as in claim 8, wherein the acute renal failure is ischemia-reperfusion-induced acute renal failure.

30 20. The compound for use as in claim 8, wherein the acute renal failure is sepsis-associated acute renal failure.

21. The compound for use as in claim 8, wherein the acute renal failure is toxic acute renal failure due to chemotherapy treatment.

35 **Patentansprüche**

1. Doppelsträngige siRNA-Verbindung mit der Struktur:

40 5' ugaaggugaaaaauuucuc - Z 3' (Antisense-Strang SEQ ID NO: 48)
3' Z'-acuuuccacuuuaagag (Sense-Strang SEQ ID NO: 25);

wobei jedes a, c, u und g ein Ribonukleotid ist und jedes darauf folgende Ribonukleotid mit dem nächsten Ribonukleotid durch eine kovalente Bindung verbunden ist; und

45 wobei jedes von Z und Z' vorhanden sein oder fehlen kann, wenn es vorhanden ist, jedoch dTdT ist und kovalent an den 3'-Terminus des Strangs gebunden ist, in dem es vorhanden ist; und wobei alternierende Ribonukleotide in sowohl dem Antisense-Strang als auch dem Sense-Strang in ihrem Zuckerrest so modifiziert sind, dass eine 2'-O-Methylgruppe vorhanden ist und mit 2'-O-Methylzucker modifizierte Ribonukleotide an dem 5'-Terminus und dem 3'-Terminus des Antisense-Strangs vorhanden sind und unmodifizierte Ribonukleotide an dem 5'-Terminus und 3'-Terminus des Sense-Strangs vorhanden sind.

50

2. Verbindung nach Anspruch 1, wobei die kovalente Bindung eine Phosphodiesterbindung ist.

3. Verbindung nach Anspruch 1 oder 2, wobei Z und Z' beide fehlen.

55 4. Verbindung nach Anspruch 1, 2 oder 3, wobei das Ribonukleotid am 3'-Terminus und das Ribonukleotid am 5'-Terminus im Antisense-Strang und dem Sense-Strang nicht-phosphoryliert sind.

5. Verbindung nach Anspruch 1, 2 oder 3, wobei das Ribonukleotid am 3'-Terminus im Antisense-Strang und das Ribonukleotid am 3'-Terminus im Sense-Strang phosphoryliert sind.

5 6. Pharmazeutische Zusammensetzung, umfassend die Verbindung nach einem der Ansprüche 1 bis 5 in einer wirksamen Menge, um die Expression eines humanen p53-Gens herunter zu regulieren; und einen Träger.

10 7. Verbindung nach einem der Ansprüche 1 bis 5 zur Verwendung in der Therapie.

10 8. Verbindung nach einem der Ansprüche 1-5 zur Verwendung in der Behandlung oder Prävention von akutem Nierenversagen.

15 9. Verbindung zur Verwendung nach Anspruch 8, wobei das akute Nierenversagen größerer Herzoperation oder Gefäßoperation folgt.

15 10. Verbindung zur Verwendung nach Anspruch 9, wobei das akute Nierenversagen größerer Herzoperation folgt.

15 11. Verbindung nach einem der Ansprüche 1-5 zur Verwendung in der Behandlung der Alopezie.

20 12. Verbindung nach einem der Ansprüche 1-5 zur Verwendung in der Verbesserung des Überlebens von Transplantatgewebe nach Transplantation.

20 13. Verbindung nach einem der Ansprüche 1-5 zur Verwendung in der Prävention von ischämischem akutem Nierenversagen bei einem Nierentransplantatpatienten.

25 14. Verbindung zur Verwendung nach einem der Ansprüche 8 bis 13, wobei die Verbindung durch systemische Verabreichung zu verabreichen ist.

25 15. Verbindung nach einem der Ansprüche 1-5 zur Verwendung in der Behandlung von Hirnverletzung und Verletzung des Rückenmarks.

30 16. Verbindung zur Verwendung nach Anspruch 15, wobei die Hirnverletzung ein Krampfanfall ist.

30 17. Verbindung nach einem der Ansprüche 1-5 zur Verwendung in der Behandlung von durch Cisplatin induzierter Schwerhörigkeit.

35 18. Verbindung zur Verwendung nach einem der Ansprüche 11 oder 17, wobei die Verbindung durch topische Verabreichung zu verabreichen ist.

40 19. Verbindung zur Verwendung nach Anspruch 8, wobei das akute Nierenversagen durch Ischämie-Reperfusion induziertes akutes Nierenversagen ist.

45 20. Verbindung zur Verwendung nach Anspruch 8, wobei das akute Nierenversagen mit Sepsis assoziiertes akutes Nierenversagen ist.

45 21. Verbindung zur Verwendung nach Anspruch 8, wobei das akute Nierenversagen toxicisches akutes Nierenversagen aufgrund von Chemotherapiebehandlung ist.

50 **Revendications**

1. Composé d'ARNsi à double brin présentant la structure suivante :

5' ugaaggugaaaaauucuc - Z 3' (brin antisens SEQ ID N° 48)
 3' Z'-acuuucccacuuuaagag (brin antisens SEQ ID N° 25)

55 où chaque a, c, u et g représente un ribonucléotide et où chaque ribonucléotide consécutif est lié au ribonucléotide suivant par une liaison covalente ; et
 où chacun de Z et Z' peut être présent ou absent, mais s'il est présent, c'est le dTdT et il est attaché de manière

5 covalente à la terminaison 3' du brin dans lequel il se trouve ; et où les ribonucléotides alternant dans le brin antisens et dans le brin sens sont modifiés dans leur résidu de sucre de sorte qu'un groupe 2'-O-méthyle est présent et que des ribonucléotides modifiés par un sucre 2'-O-méthyle sont présents à la terminaison 5' et à la terminaison 3' du brin antisens et que des ribonucléotides non modifiés soient présents à la terminaison 5' et à la terminaison 3' du brin sens.

2. Composé selon la revendication 1, dans lequel la liaison covalente est une liaison phosphodiester.
3. Composé selon la revendication 1 ou 2, dans lequel Z et Z' sont tous deux absents.
4. Composé selon la revendication 1, 2 ou 3, dans lequel le ribonucléotide au niveau de la terminaison 3' et le ribonucléotide à la terminaison 5' dans le brin antisens et dans le brin sens ne sont pas phosphorylés.
5. Composé selon la revendication 1, 2 ou 3, dans lequel le ribonucléotide au niveau de la terminaison 3' dans le brin antisens et le ribonucléotide à la terminaison 3' dans le brin sens sont phosphorylés.
6. Composition pharmaceutique contenant le composé de l'une quelconque des revendications 1 à 5 en quantité suffisant à réguler vers le bas l'expression d'un gène p53 humain ; et un véhicule.
7. Composé selon l'une quelconque des revendications 1 à 5, utilisé en thérapie.
8. Composé selon l'une quelconque des revendications 1 à 5, utilisé pour traiter ou pour prévenir une défaillance rénale aiguë.
9. Composé utilisé selon la revendication 8, dans lequel la défaillance rénale aiguë suit une intervention chirurgicale cardiaque ou vasculaire majeure.
10. Composé selon la revendication 9, dans lequel la défaillance rénale aiguë suit une intervention chirurgicale cardiaque majeure.
11. Composé selon l'une quelconque des revendications 1 à 5, utilisé pour traiter une alopecie.
12. Composé selon l'une quelconque des revendications 1 à 5, utilisé pour améliorer la survie de tissu greffé après transplantation.
13. Composé selon l'une quelconque des revendications 1 à 5, utilisé pour prévenir une défaillance rénale aiguë ischémique chez un patient ayant subi une transplantation rénale.
14. Composé utilisé selon l'une quelconque des revendications 8 à 13, dans lequel ledit composé doit être administré par administration systémique.
15. Composé selon l'une quelconque des revendications 1 à 5, utile pour traiter une lésion cérébrale et une lésion de la moelle épinière.
16. Composé selon la revendication 15, dans lequel la lésion cérébrale est une convulsion.
17. Composé selon l'une quelconque des revendications 1 à 5, utilisée pour traiter une surdité induite par la cisplatine.
18. Composé utilisé selon l'une des revendications 11 à 17, dans lequel ledit composé doit être administré par administration topique.
19. Composé utilisé selon la revendication 8, dans lequel la défaillance rénale aiguë est une défaillance rénale aiguë induite par une ischémie-reperfusion.
20. Composé utilisé selon la revendication 8, dans lequel la défaillance rénale aiguë est une défaillance rénale aiguë associée à une sepsie.
21. Composé utilisé selon la revendication 8, dans lequel la défaillance rénale aiguë est une défaillance rénale aiguë

toxique due à un traitement chimiothérapeutique.

5

10

15

20

25

30

35

40

45

50

55

Figure 1

Homo sapiens tumor protein p53 (Li-Fraumeni syndrome) (TP53), mRNA
gi|8400737|ref|NM_000546.2.

Hum-TP53	1	ACTTGTATG GCGACTGTCC AGCTTGTGC CAGGACCTC GCAGGGTTG ATGGGATTGG GGTTTTCCCC	70
Hum-TP53	71	TCCCATGTGC TCAAGACTGG CGCTAAAAGT TTTGAGCTTC TCAAAAGTCT AGAGCCACCG TCCAGGGAGC	140
Hum-TP53	141	AGGTAGCTGC TGGGCTCCGG GGACACTTTC CGTTCGGGCT GGGAGCGTGC TTTCACGAC GGTGACACGC	210
Hum-TP53	211	TTCCCTGGAT TGGCAGCCAG ACTGCCTTCC GGGTCACTGC <u>CATGGAGGAG</u> CCCCAGTCAG ATCCTAGCGT	280
Hum-TP53	281	CGAGCCCCCT CTGAGTCAGG AACATTTTC AGACCTATGG AAACACTTC CTGAAAACAA CGTTCTGTCC	350
Hum-TP53	351	CCCTTGCCGT CCCAAGCAAT GGATGATTG ATGCTGTCCC CGGACGATAT TGAACAATGG TTCACTGAAG	420
Hum-TP53	421	ACCCAGGTCC AGATGAAGCT CCCAGAATGC CAGAGGCTGC TCCCCGCGTG GCCCCTGCAC CAGCAGCTCC	490
Hum-TP53	491	TACACCGGCG GCCCTGCAC CAGCCCCCTC CTGGCCCTG TCATCTTCIG TCCCTTCCCA GAAAACCTAC	560
Hum-TP53	561	CAGGGCAGCT ACGGTTCCG TCTGGCTTC TTGCATTCTG GGACAGCCAA GTCTGTGACT TGCACGTACT	630
Hum-TP53	631	CCCCCTGCCCT CAACAAGATG TTTGCCAAC TGCCCAAGAC CTGCCCTGTG CAGCTGTGGG TTGATTCCAC	700
Hum-TP53	701	ACCCCCGCC GGCACCCGCG TCCGCGCCAT GGCCATCTAC AAGCAGTCAC AGCACATGAC GGAGGTTGTG	770
Hum-TP53	771	AGGCCTGCTGCC CCCACCATGA GCGCTGCTCA GATAGCGATG GTCTGGCCCC TCCTCAGCAT CTTATCCGAG	840
Hum-TP53	841	TGGAAGGAAA TTGCGTGTG GAGTATTGG ATGACAGAAA CACTTTCGA CATAGTGTGG TGGTGCCTA	910
Hum-TP53	911	TGAGCCGCCT GAGGTTGGCT CTGACTGTAC CACCATCCAC TACAACATACA TGTGTAACAG TTCCCTGCATG	980
Hum-TP53	981	GGCGGCATGA ACCGGAGGCC CATCCTCACC ATCATCACAC TGGAAGACTC CAGTGGTAAT CTACTGGGAC	1050
Hum-TP53	1051	GGAACAGCTT TGAGGTGCGT GTTGTGCCT GTCCCTGGAG AGACCGGCCG ACAGAGGAAG AGAACATCCG	1120
Hum-TP53	1121	CAAGAAAGGG GAGCCTCACC ACGAGCTGCC CCCAGGGAGC ACTAACGAG CACTGCCAA CAACACCAGC	1190
Hum-TP53	1191	TCCTCTCCCC AGCCAAAGAA GAAACCACTG GATGGAGAAT ATTTCACCT TCAGATCCGT GGGCGTGAGC	1260
Hum-TP53	1261	GCTTCGAGAT GTTCCGAGAG CTGAATGAGG CCTTGGAACT CAAGGATGCC CAGGCTGGGA AGGAGCCAGG	1330
Hum-TP53	1331	GGGGAGCAGG GCTCACTCCA GCCACCTGAA GTCCAAAAG GGTCACTA CCTCCGCCA TAAAAAACTC	1400
Hum-TP53	1401	ATGTTCAAGA <u>CAGAAGGGCC</u> TGACTCAGAC <u>TGACATTCTC</u> CACTTCTGT TCCCCACTGA CAGCCTCCCA	1470
Hum-TP53	1471	CCCCCATCTC TCCCTCCCT GCCATTTGG GTTGTGGCT TTTGAACCT TGGTGTGCAAT AGGTGTGCGT	1540
Hum-TP53	1541	CAGAACGACC CAGGACTTCC ATTTGCTTGC TCCCGGGCT CCACGTACA AGTTGGCCTG CACTGGTGT	1610
Hum-TP53	1611	TTGTTGTGGG GAGGAGGATG GGGAGTAGGA CATAACAGCT TAGATTAA GGTTTTACT GTGAGGGATG	1680
Hum-TP53	1681	TTTGGGAGAT GTAAGAAATG TTCTTGCACT TAAGGGTAG TTTACAATCA GCCACATTCT AGGTAGGTAG	1750
Hum-TP53	1751	GGGCCCACTT CACCGTACTA ACCAGGGAG CTGTCCCTCA TGTTGAATT TCTCTAACCTT CAAGGCCCAT	1820
Hum-TP53	1821	ATCTGTAAA TGCTGGCATT TGCACCTACC TCACAGAGTG CATTGTGAGG GTTAATGAAA TAATGTACAT	1890
Hum-TP53	1891	CTGGCCTTGA AACCCACCTTT TATTACATGG GGTCTAAAAC TTGACCCCT TGAGGGTGCCT TGTTCCCTCT	1960
Hum-TP53	1961	CCCTCTCCCT GTTGGCTGGT GGGTTGGTAG TTTCTACAGT TGGCAGCTG GTTAGGTAGA GGGAGTTGTC	2030
Hum-TP53	2031	AAGTCTTGCT GGCCAGCCA AACCCCTGTCT GACAAACCTCT TGGTCGACCT TAGTACCTAA AAGGAAATCT	2100

Hum-TP53	2101	CACCCCATCC CACACCCTGG AGGATTTCAT CTCTTGATA TGATGATCTG GATCCACCAA GACTTGT	2170
Hum-TP53	2171	ATGCTCAGGG TCAATTTCTT TTTTCTTTT TTTTTTTTTT TTTCTTTTC TTTGAGACTG GGTCTCGCTT	2240
Hum-TP53	2241	TGTTGCCAG GCTGGAGTGG AGTGGCGTGA TCTTGGCTTA CTGCAGCCTT TGCCTCCCCG GCTCGAGCAG	2310
Hum-TP53	2311	TCCTGCCTCA GCCTCCGGAG TAGCTGGGAC CACAGGTTCA TGCCACCATG GCCAGCCAAC TTTTGCATGT	2380
Hum-TP53	2381	TTTGTAGAGA TGGGGTCTCA CAGTGTGCC CAGGCTGGTC TCAAACCTC GGGCTCAGGC GATCCACCTG	2450
Hum-TP53	2451	TCTCAGCCTC CCAGAGTGCT GGGATTACAA TTGTGAGCCA CCACGTGGAG CTGGAAGGGT CAACATCTT	2520
Hum-TP53	2521	TACATTCTGC AAGCACATCT GCATTTCAC CCCACCCCTTC CCCTCCTTCT CCCTTTTAT ATCCCATT	2590
Hum-TP53	2591	TATATCGATC TCTTATTTA CAATAAAACT TTGCTGCCA	2629

Note that the start (ATG) and stop (TGA) codons are underlined

Figure 2

Protein - Homo sapiens tumor protein p53 (Li-Fraumeni syndrome) (TP53)

Hum_TP53_prot 1 MEEPQSDPSV EPPLSQETFS DLWKLLPENN VLSPLPSQAM DDMLSPDDI EQWFTEDPGP DEAPRMPEAA
Hum_TP53_prot 71 PRVAPAPAAP TPAAPAPAPS WPLSSSVPSQ KTYQGSYGFR LGFLHSGTAK SVTCTYSPAL NKMFCQLAKT
Hum_TP53_prot 141 CPVQLWVDST PPPGTRVRAM AIYKQSQHMT EVVRRCPHHE RCSDSDGLAP PQHLIRVEGN LRVEYLDLDRN
Hum_TP53_prot 211 TFRHSVVVPY EPPEVGSDCT TIHYNYMCNS SCMMGMNRRP ILTIITLEDS SGNLLGRNSF EVRVCACPGR
Hum_TP53_prot 281 DRRTEEEENLR KKGEPHHELP PGSTKRALPN NTSSSPQPKK KPLDGEYFTL QIRGRERFEM FRELNEALEL
Hum_TP53_prot 351 KDAQAGKEPG GSRAHSSHLK SKKGQSTSRRH KKL MFKTEGP DSD 393

Variations in other human entries in GeneBank (gi- 23491728; gi-35209; gi-13097806):

R72 -> P
R273 -> H
P278 -> A
P309 -> S

Figure 3





Figure 4

Figure 5:




Figure 6:





Figure 7 :



REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- WO 0136646 A, Glover [0003]
- WO 2004015107 A, Atugen [0004]
- WO 0244321 A, Tuschl [0004]
- WO 5898031 A [0004]
- WO 6107094 A, Crooke [0004]
- US 6593353 B [0007]
- WO 03064625 A [0013]
- US 5587361 A [0039]
- US 6242589 B [0039]
- US 6277967 B [0039]
- US 6326358 B [0039]
- US 5399676 A [0039]
- US 5489677 A [0039]
- US 5596086 A [0039]
- US 20040063654 A, Davis [0059]
- US 5225182 A [0061]
- US 5169383 A [0061]
- US 5167616 A [0061]
- US 4959217 A [0061]
- US 4925678 A [0061]
- US 4487603 A [0061]
- US 4486194 A [0061]
- US 4447233 A [0061]
- US 4447224 A [0061]
- US 4439196 A [0061]
- US 4475196 A [0061]
- WO 9323569 A, Draper [0082]
- US 6121426 A [0083]
- US 20040019001 A [0084]
- EP 2005008891 W [0089]
- US 4666828 A [0098]
- US 4683202 A [0098]
- US 4801531 A [0098]
- US 5192659 A [0098]
- US 5272057 A [0098]

Non-patent literature cited in the description

- GIL et al. *Apoptosis*, 2000, vol. 5, 107-114 [0002]
- ELBASHIR et al. *Nature*, 2001, vol. 411, 494-498 [0002]
- CAPLEN et al. *Proc Natl Acad Sci*, 2001, vol. 98, 9742-9747 [0002]
- FIRE et al. *Nature*, 1998, vol. 391, 806 [0003]
- AMBROS V. *Nature*, 2004, vol. 431 (7006), 350-355 [0003]
- BARTEL DP. *Cell*, 23 January 2004, vol. 116 (2), 281-97 [0003]
- ELBASHIR et al. *Genes Dev.*, 2001, vol. 15, 188 [0003]
- BERNSTEIN et al. *Nature*, 2001, vol. 409, 363-6 [0003]
- LEE et al. *Nature*, 2003, vol. 425, 415-9 [0003]
- MCMANUS ; SHARP. *Nature Rev Genet*, 2002, vol. 3, 737-47 [0003]
- PADDISON ; HANNON. *Curr Opin Mol Ther.*, June 2003, vol. 5 (3), 217-24 [0003]
- BERNSTEIN E. ; DENLI AM. ; HANNON GJ. The rest is silence. *RNA*. I, 2001, vol. 7 (11), 1509-21 [0003]
- NISHIKURA K. A short primer on RNAi: RNA-directed RNA polymerase acts as a key catalyst. *Cell*. I 16, 2001, vol. 107 (4), 415-8 [0003]
- CHALK AM ; WAHLESTEDT C ; SONNHAMMER EL. Improved and automated prediction of effective siRNA. *Biochem. Biophys. Res. Commun.*, 18 June 2004, vol. 319 (1), 264-74 [0004]
- SIOUD M ; LEIRDAL M. Potential design rules and enzymatic synthesis of siRNAs. *Methods Mol Biol.*, 2004, vol. 252, 457-69 [0004]
- LEVENKOVA N ; GU Q ; RUX JJ. Gene specific siRNA selector. *Bioinformatics*, 2004, vol. 20 (3), 430-2 [0004]
- UI-TEI K ; NAITO Y ; TAKAHASHI F ; HARAGUCHI T ; OHKI-HAMAZAKI H ; JUNI A ; UEDA R ; SAIGO K. Guidelines for the selection of highly effective siRNA sequences for mammalian and chick RNA interference. *Nucleic Acids. Res.*, 2004, vol. 32 (3), 936-48 [0004]
- LIU Y ; BRAASCH DA ; NULF CJ ; COREY DR. Efficient and isoform-selective inhibition of cellular gene expression by peptide nucleic acids. *Biochemistry*, 2004, vol. 43 (7), 1921-7 [0004]
- CHIU YL ; RANA TM. siRNA function in RNAi: a chemical modification analysis. *RNA*, September 2003, vol. 9 (9), 1034-48 [0004]
- PADDISON et al. *PNAS*, 2002, vol. 99, 1443-1448 [0005]
- PADDISON et al. *Genes & Dev*, 2002, vol. 16, 948-958 [0005]

- **SUI** et al. *PNAS*, 2002, vol. 8, 5515-5520 **[0005]**
- **BRUMMELKAMP** et al. *Science*, 2002, vol. 296, 550-553 **[0005]** **[0099]**
- **TOLENTINO** et al. *Retina*, February 2004, vol. 24 (1), 132-138 **[0006]** **[0059]**
- **GOTTLIEB** et al. *Biochem.Biophys. Acta*, 1996, vol. 1287, 77 **[0007]**
- **KOMAROV PG** et al. A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. *Science*, 1999, vol. 285 (5434), 53 **[0007]**
- **BOTCHAREV** et al. p53 is essential for Chemotherapy -induced Hair Loss. *Cancer Research*, 2000, vol. 60, 5002-5006 **[0007]**
- **GEORGE COTSARELIS** ; **SARAH E. MILLAR**. Towards a molecular understanding of hair loss and its treatment. *TRENDS in Molecular Medicine*, 2001, vol. 7 (7 **[0008]**)
- **KOMAROV** et al. *Science*, 10 September 1999, vol. 285 (5434), 1733-7 **[0012]**
- **SUPAVEKIN** et al. *Kidney Int.*, 2003, vol. 63 (5), 1714-24 **[0012]**
- **CZAUDERNA** et al. *Nucleic Acids Research*, 2003, vol. 31 (11), 2705-2716 **[0025]**
- **BOURDON** et al. *Genes Dev.*, 2005, vol. 19, 2122-2137 **[0026]**
- **AUSUBEL** et al. *Current Protocols in Molecular Biology*. John Wiley and Sons, 1988 **[0027]**
- **SHEN** et al. *FEBS letters*, 2003, vol. 539, 111-114 **[0059]**
- **XIA** et al. *Nature Biotechnology*, 2002, vol. 20, 1006-1010 **[0059]**
- **REICH** et al. *Molecular Vision*, 2003, vol. 9, 210-216 **[0059]**
- **SORENSEN** et al. *J.Mol.Biol.*, 2003, vol. 327, 761-766 **[0059]**
- **LEWIS** et al. *Nature Genetics*, 2002, vol. 32, 107-108 **[0059]**
- **SIMEONI** et al. *Nucleic Acids Research*, 2003, vol. 31 (11), 2717-2724 **[0059]**
- **SOUTSCHEK** et al. *Nature*, 2004, vol. 432, 173-177 **[0059]**
- **LORENZ** et al. *Bioorg. Med. Chemistry. Lett.*, 2004, vol. 14, 4975-4977 **[0059]**
- **BEAUCAGE S.L.** ; **IYER R.P.** *Tetrahedron*, 1992, vol. 48, 2223-2311 **[0080]**
- **BEAUCAGE S.L.** ; **IYER R.P.** *Tetrahedron*, 1993, vol. 49, 6123-6194 **[0080]**
- **CARUTHERS M.H.** *Methods Enzymol.*, 1987, vol. 154, 287-313 **[0080]**
- **ECKSTEIN F.** *Annu. Rev. Biochem.*, 1985, vol. 54, 367-402 **[0080]**
- **SPROAT B.** Kap. Humana Press, 2005, vol. 2, 17-31 **[0080]**
- **PINGOUD A.** Kap. IRL Press, 1989, vol. 7, 183-208 **[0080]**
- **SPROAT B.** Kap. Humana Press 2005, vol. 2, 17-31 **[0080]**
- **USMAN** et al. *J. Am. Chem. Soc.*, 1987, vol. 109, 7845 **[0081]**
- **SCARINGE** et al. *Nucleic Acids Res.*, 1990, vol. 18, 5433 **[0081]**
- **WINCOTT** et al. *Nucleic Acids Res.*, 1995, vol. 23, 2677-2684 **[0081]**
- **WINCOTT** et al. *Methods Mol. Bio.*, 1997, vol. 74, 59 **[0081]**
- **MOORE** et al. *Science*, 1992, vol. 256, 9923 **[0082]**
- **SHABAROVA** et al. *Nucleic Acids Research*, 1991, vol. 19, 4247 **[0082]**
- **BELLON** et al. *Nucleosides & Nucleotides*, 1997, vol. 16, 951 **[0082]**
- **BELLON** et al. *Bioconjugate Chem.*, 1997, vol. 8, 204 **[0082]**
- **SAMBROOK** et al. *Molecular Cloning: A Laboratory Manual*. Cold Spring Harbor Laboratory Press, 1989 **[0098]**
- **AUSUBEL** et al. *Current Protocols in Molecular Biology*. John Wiley and Sons, 1989 **[0098]**
- **PERBAL**. *A Practical Guide to Molecular Cloning*. John Wiley & Sons, 1988 **[0098]**
- Recombinant DNA. **WATSON** et al. *Scientific American Books* **[0098]**
- *Genome Analysis: A Laboratory Manual Series*. Cold Spring Harbor Laboratory Press, 1998, vol. 1-4 **[0098]**
- *PCR Protocols: A Guide To Methods And Applications*. Academic Press, 1990 **[0098]**
- **TESTONI** et al. *Blood*, 1996, vol. 87, 3822 **[0098]**
- **DIRAC** ; **BERNARDS**. Reversal of senescence in mouse fibroblasts through lentiviral suppression of p53. *J. Biol. Chem.*, 2003, vol. 278, 11731 **[0099]**
- **MIYAJI T** ; **HU X** ; **YUEN PS** ; **MURAMATSU Y** ; **IYER S** ; **HEWITT SM** ; **STAR RA**. Ethyl pyruvate decreases sepsis-induced acute renal failure and multiple organ damage in aged mice. *Kidney Int. Nov*, 2003, vol. 64 (5), 1620-31 **[0110]**
- *J Am Soc Nephrol.*, vol. 14 (1), 128-38 **[0111]**

**OLIGORIBONUKLEOTIDOK ÉS AZOK ALKALMAZÁSI ELJÁRÁSAI
ALOPÉCIA, AKUT VESSELÉGTELÉSÉG ÉS MÁS BETEGSÉGEK
KEZELÉSÉRE**

Szabadalmi igénypontok

1. Kétszálú siRNS-vegyület, amely a következő szerkezettel rendelkezik:
 $5'$ ogaaggugaaauauucuc - Z $3'$ (antiszisz szál SEQ ID NO:48)
 $3'$ Z' -acauccacacuuauaagag. (szensz szál SEQ ID NO:25);
 ahol mindegyik a, c, u és g jelentése egy ribonukleotid és mindegyik egymást követő ribonukleotid a következő ribonukleotiddal egy kovalens kötés által van összekapcsolva; és
 ahol Z és Z' közül mindegyik rendelkezésre állhat vagy hiányozhat, viszont ha rendelkezésre áll, akkor jelentése dTdT és kovalensen van kötve a szálnak a $3'$ -végéhez (terminálisához), amelyben rendelkezésre áll; és
 ahol a váltakozó ribonukleotidokhoz tartozó cukormaradék minden az antiszisz szálban minden a szensz szálban módosított oly módon, hogy egy 2'-O-metil csoport áll rendelkezésre és 2'-O-metil-cukor-módosított ribonukleotidok állnak rendelkezésre az antiszisz szálnak az $5'$ -végén (terminálisán) és a $3'$ -végén (terminálisán) és módosítatlan ribonukleotidok állnak rendelkezésre a szensz szálnak az $5'$ -végén (terminálisán) és a $3'$ -végén (terminálisán).
2. Vegyület az 1. igénypont szerint, ahol a kovalens kötést egy foszfodiészter kötés képezi.
3. Vegyület az 1. vagy 2. igénypont szerint, ahol Z és Z' mindenketten (egyaránt) hiányoznak.
4. Vegyület az 1., 2. vagy 3. igénypont szerint, ahol a ribonukleotid a $3'$ -végén (terminálison) és a ribonukleotid az $5'$ -végén (terminálison) az antiszisz szálban és a szensz szálban nem foszforiláltak.
5. Vegyület az 1., 2. vagy 3. igénypont szerint, ahol a ribonukleotid a $3'$ -végén (terminálison) az antiszisz szálban és a ribonukleotid az $3'$ -végén (terminálison) a szensz szálban foszforiláltak.
6. Gyógyászati készítmény, amely a következőket tartalmazza: az 1-től 5.-ig igénypontok bármelyike szerinti vegyületet egy hatásos mennyiségben, egy humán p53 gén expressziójának a csökkentő szabályozására; és egy hordozót.
7. Vegyület az 1-től 5.-ig igénypontok bármelyike szerint, terápiában történő alkalmazásra.
8. Vegyület az 1-5. igénypontok bármelyike szerint, akut veselégtelenség kezelésében vagy megelőzésében történő alkalmazásra.
9. Vegyület alkalmazás céljából a 8. igénypont szerint, ahol az akut veselégtelenség komoly (nagyobb) szívsebészeti beavatkozás (műtét) vagy érszabézszi beavatkozás (műtét) után következik be.
10. Vegyület alkalmazás céljából a 9. igénypont szerint, ahol az akut veselégtelenség komoly (nagyobb) szívsebészeti beavatkozás (műtét) után következik be.
11. Vegyület az 1-5. igénypontok bármelyike szerint, alopécia kezelésében történő alkalmazásra.
12. Vegyület az 1-5. igénypontok bármelyike szerint, átültetett (graft) szövet túlélésének a javításában történő alkalmazásra, transzplantációt (átültetést) követően.

13. Vegyület az 1-5. igénypontok bármelyike szerint, iszkémiás akut veszelégtelenség megelőzésében történő alkalmazásra, egy vesecátültetésen (vese-transzplantáció) átesett páciensnél.
14. Vegyület alkalmazás céljából a 8.-tól 13.-ig igénypontok bármelyike szerint, ahol a nevezett vegyületet szisztematikus adagolás révén kell adagolni.
15. Vegyület az 1-5. igénypontok bármelyike szerint, agykárosodás és gerincvelő (gerincagy) károsodás kezelésében történő alkalmazásra.
16. Vegyület alkalmazás céljából a 15. igénypont szerint, ahol az agykárosodást egy görcsroham (angolul: „seizure”) képezi.
17. Vegyület az 1-5. igénypontok bármelyike szerint, císzplatin által indukált sükütség (nagyothalás) kezelésében történő alkalmazásra.
18. Vegyület alkalmazás céljából a 11. vagy 17. igénypont szerint, ahol a nevezett készítményt topikális adagolás révén kell adagolni.
19. Vegyület alkalmazás céljából a 8. igénypont szerint, ahol az akut veszelégtelenséget iszkémia-reperfúzió által indukált akut veszelégtelenség képezi.
20. Vegyület alkalmazás céljából a 8. igénypont szerint, ahol az akut veszelégtelenséget szepszissel kapcsolatos akut veszelégtelenség képezi.
21. Vegyület alkalmazás céljából a 8. igénypont szerint, ahol az akut veszelégtelenséget toxikus akut veszelégtelenség képezi, amely kemoterápiás kezelés következménye.